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ABSTRACT 
Neurodegenerative diseases affect a staggering proportion of the population. 
Many neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral 
sclerosis, and Parkinson’s disease exhibit significant metabolic and bioenergetic changes 
both systemically and in the central nervous system. Accordingly, abnormalities in 
mitochondrial function are also present early in the pathogenesis of neurodegenerative 
diseases, leading to dysregulation of mitochondrial and metabolic signaling pathways and 
general neuronal dependence on anaerobic metabolism. Specifically, the electron 
transport chain function is reduced both systemically and in brains of individuals affected 
by Alzheimer’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease. The goal 
of this dissertation is to better understand the mechanisms of mitochondrial retrograde 
signaling that may play a role in neurodegeneration.  
In our first study, we show that mtDNA depletion of neuroblastoma cell lines 
significantly alters mitochondrial retrograde signaling in such a way that promotes 
upregulation of respiratory chain subunits, but inhibits mitochondrial mass as a whole. 
Further investigation into the bioenergetic status of these mtDNA-depleted cells suggests 
that these non-respiratory mitochondria are unable to contribute to the cell energetically, 
and are thus a metabolic liability. This study provides insight into mitochondrial 
signaling processes that may be present in neurodegenerative disorders.  
Next, we examine the role of a ketogenic diet on mitochondrial signaling 
pathways in mouse brains. We show in this study that a ketogenic diet promotes a 
number of favorable metabolic changes in mice including reduction of systemic insulin 
resistance, an increase in the mitochondrial master regulator PGC1α and its relative 
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PGC1β, and an increase in some elements of mitochondrial mass. This study lays 
mechanistic groundwork for the potential use of a ketogenic diet in neurodegenerative 
disorders.  
We then describe the generation of cybrid lines to evaluate the role of mtDNA in 
Alzheimer’s disease, mild cognitive impairment, amyotrophic lateral sclerosis, and 
normal aging. These lines have shown us that mtDNA from individuals with these 
various conditions confer significant mitochondrial dysfunction to their respective cell 
lines, and that these lines will continue to provide significant insight into the role of 
mtDNA and mitochondrial function in disease states and aging. 
Finally, we show that the pan-neurotrophin receptor p75NTR is necessary for 
estrogen-induced sympathetic nerve remodeling in the mouse uterus. This physiological 
phenomenon involves cyclical degeneration and regeneration of sympathetic nerves to 
uterine smooth muscle, and is an important model for studying axonal changes in normal 
degenerative and regenerative events.  
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CHAPTER I: Introduction 
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Neurodegenerative disorders affect a staggering proportion of the population. 
Alzheimer’s disease (AD) alone affects approximately 5.4 million Americans; one in 
eight individuals over 65 have AD, and 40-50% of those over 85 years of age are affected 
(Thies & Bleiler, 2011). While different neurodegenerative disorders have distinct 
features and pathophysiological changes, it seems that metabolic and mitochondrial 
dysfunction play a central role in many types of neurodegeneration. The overarching goal 
of this dissertation is to better understand the signals that govern mitochondrial function 
that may protect or lead to degeneration. In this Introduction, we will review the role of 
mitochondrial dysfunction in AD to establish a case for metabolic dysregulation in 
neurodegeneration.  
Is sporadic Alzheimer’s disease a primary or secondary amyloidosis? 
In 1906, Alois Alzheimer described a 55-year old patient with severe dementia. 
Post-mortem evaluation revealed extensive amyloid plaques in this patient’s cerebral 
cortex (Alzheimer, 1907; Verhey, 2009). In the 1970s, Katzman and colleagues extended 
the term “Alzheimer’s disease” to include senile dementia, a condition not previously 
thought to critically overlap with the pre-senile dementia disorder described by 
Alzheimer.  This was accomplished by using the presence of amyloid plaques and 
neurofibrillary tangles to argue the existence of a common etiology, and infer that all 
tangle and plaque dementias were a single disease (Katzman, 1976). The identification of 
deterministic mutations within the APP gene, from which beta amyloid (Aβ) derives 
(Goate et al., 1991), subsequently gave rise to the amyloid cascade hypothesis (Hardy & 
Allsop, 1991; Hardy & Higgins, 1992).  This hypothesis has profoundly influenced AD 
conceptual thinking. Most investigators in the AD field currently assume that pre-senile, 
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autosomal dominant cases of AD with APP mutations are instigated through abnormal 
amyloid processing, although the possibility that disease arises as a consequence of 
perturbed APP function has not been fully excluded (Galvan et al., 2006).  
Problems arise when using the amyloid cascade hypothesis to explain the 
pathophysiology of senile, sporadic forms of AD. For example, unlike in autosomal 
dominant forms, no apparent mutations exist in APP or processing proteins. Even genetic 
polymorphisms in APP seem to have little or no effect on sporadic AD risk (Guyant-
Marechal et al., 2007). Amyloid levels in the brain can exist in the absence of clinical 
symptoms, and elevated Aβ levels preclude biochemical and clinical signs of 
neurodegeneration by years. Also, it is well recognized that elevated brain parenchyma 
Aβ does not necessarily associate with clinical dementia (Berlau et al., 2009; Sperling et 
al., 2011). If amyloidosis were sufficient to cause disease, it seems unlikely that 
individuals with elevated Aβ could remain asymptomatic for so long.   
A key point to keep in mind, though, is that even if all AD cases include brain 
amyloidosis, the question of whether particular forms of AD represent primary or 
secondary amyloidoses must still be considered.  The extremely rare APP mutation cases 
have the highest likelihood of being primary amyloidoses.  In the absence of 
deterministic mutations, other physiologic events may be required to induce amyloidosis. 
If this presumption is correct, then these cases are secondary amyloidoses.  Recently, it 
has become abundantly clear that APP metabolism is an exquisitely regulated process, 
and bioenergetic status or states indeed regulate APP metabolism (Gabuzda et al., 1994; 
Gasparini et al., 1997; Khan et al., 2000; Webster et al., 1998).   
Mitochondria in AD 
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Mitochondrial structural and functional perturbations in AD are well documented. 
For example, in 1985 the morphology of mitochondria in degenerating dendrites from 
brains of AD patients was noted to be abnormal, and postulated to perhaps even precede 
dendritic degeneration (Saraiva et al., 1985). One year later, Peterson et al. described 
altered calcium homeostasis in AD patient fibroblasts, a finding potentially consistent 
with the presence of a systemic bioenergetic defect (Peterson & Goldman, 1986). The 
activities of several mitochondria-localized enzymes, including α-ketoglutarate 
dehydrogenase complex and pyruvate dehydrogenase complex, are reduced in AD, and 
this observation encouraged some to propose AD is a disease of perturbed brain energy 
metabolism (Blass et al., 2002; Gibson et al., 1998; Gibson et al., 1988; Sorbi et al., 
1983). 
Mitochondrial cascade hypothesis 
The apparent importance of mitochondria in AD and the inability of Aβ protein 
accumulation to fully account for the epidemiology and pathology of sporadic AD, as 
well as systemic biochemical perturbations in AD subjects, led Swerdlow and Khan to 
propose the mitochondrial cascade hypothesis (Swerdlow & Khan, 2004). Briefly, this 
hypothesis proposes that inherited mutations in mtDNA determine the basal functional 
ability of mitochondria and their ability to respond to and recover from stress signaling 
that is mediated by molecules such as reactive oxygen species (ROS). At the point at 
which a critical threshold of mitochondrial dysfunction is reached, the histopathology of 
AD develops, and includes neuronal apoptosis, β-amyloid deposition, and neurofibrillary 
tangles (Figure 1).  
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Figure 1. Visual summary of the mitochondrial cascade hypothesis. Inherited variations 
in mtDNA predispose an individual to impaired mitochondrial function; over time, 
mitochondrial injuries accumulate, and acquired mtDNA damage further enhances this 
mitochondrial impairment. While these perturbations are initially compensated for, this 
eventually proves inadequate, and the neuron begins to favor anaerobic over aerobic 
bioenergetics. Activation of various cell stress pathways, combined with a shift from 
aerobic to anaerobic profile leads to AD-typical histology: Aβ accumulation, tau 
hyperphosphorylation and neurofibrillary tangle formation in neurons, and synaptic 
degeneration.   
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Maternal transmission of AD 
Clearly, early onset familial AD is a result of inherited genetic mutations in genes 
of such enzymes as presenilin or other APP processing enzymes (Goate et al., 1991; 
Levy-Lahad et al., 1995; Sherrington et al., 1995; Wolfe et al., 1999). However, the vast 
majority of those affected by AD begin experiencing symptoms later in life. While 
genetic and environmental risk factors—such as APOEε4 allele and obesity, 
respectively—have been associated with senile dementia, it is not clear to what extent. 
Studies report that individuals with first-degree AD-affected relatives have a 4- to 10-fold 
higher risk of developing AD (Cupples et al., 2004; Farrer et al., 1997; Green et al., 2002; 
Silverman et al., 1994). Further, epidemiological studies suggest that late-onset AD 
seems to have a maternal inheritance pattern; one study even reported that individuals 
have a 3 to 9-fold increased risk of developing dementia when the AD-affected parent is 
maternal over paternal (Duara et al., 1993; Edland et al., 1996).  
This phenomenon has prompted additional endophenotype studies. An 
endophenotype is a partial manifestation of disease that implies increased risk for 
developing the disease. Studies utilizing FDG-PET scans indicate that non-demented 
individuals with AD-affected mothers have reduced brain glucose utilization that mimics 
FDG-PET scans of AD patients (Mosconi, 2005; Mosconi et al., 2007; Mosconi et al., 
2009). MRI scans reveal that adult children of AD mothers—but not of AD fathers—
have increased brain atrophy (Berti et al., 2011; Honea et al., 2011; Honea et al., 2010). 
Systemic cytochrome oxidase activity is reduced in individuals with AD-affected 
mothers, but not fathers (Mosconi et al., 2011). Additionally, non-demented adult 
children of AD mothers have elevated oxidative stress, brain Aβ accumulation, and 
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perform lower on cognitive testing (Debette et al., 2009; Mosconi et al., 2010a; Mosconi 
et al., 2010b). A summary of these endophenotype findings can be found in Table 1.  
Altogether, there is considerable evidence that late-onset AD has a maternal 
inheritance pattern. This pattern does not follow typical X-linkage genetics, as this would 
tend to affect the sons of AD mothers, but not daughters. Because mtDNA is inherited 
maternally, these data strongly support the theory that mitochondrial dysfunction is at the 
heart of AD.  
The cytochrome oxidase defect in AD is not brain-limited 
Activities of a number of mitochondrial enzymes have been shown to be reduced 
in AD. Specifically, the reduction of cytochrome oxidase (COX) activity has been well-
established. In brains of AD patients, activity of COX is significantly reduced compared 
to brains of non-demented individuals (Bosetti et al., 2002b; Kish et al., 1992; Mutisya et 
al., 1994; Parker et al., 1994a; Parker & Parks, 1995; Swerdlow & Kish, 2002; Wong-
Riley et al., 1997). Additionally, the number of COX-deficient neurons is significantly 
higher in brains from AD patients compared to control (Cottrell et al., 2001a; Cottrell et 
al., 2001b; Cottrell et al., 2002). Interestingly, this COX impairment is not brain-limited. 
Numerous studies have found a systemic COX deficit in AD patients present in both 
platelets (Bosetti et al., 2002a; Cardoso et al., 2004a; Parker et al., 1990; Parker et al., 
1994b) and fibroblasts (Curti et al., 1997).  
Cytoplasmic hybrid (cybrid) studies in which mtDNA from patient platelets is 
transferred to cell lines devoid of mtDNA (Figure 2) further perpetuate this COX defect. 
This specific biochemical defect persists over time in the AD cybrid lines (Swerdlow, 
2007; Swerdlow, 2011c; Swerdlow et al., 1997b; Trimmer et al., 2004). It has 
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Endophenotype 
Parameter Evaluated by: 
Change 
 Reference 
Brain glucose 
utilization 
FDG PET Reduced glucose 
utilization and more 
rapid glucose 
utilization decline rate 
in regions commonly 
affected in AD subjects 
 
(Mosconi, 2005; 
Mosconi et al., 
2007; Mosconi et 
al., 2009) 
Brain Volume MRI with voxel-
based 
morphometry 
More atrophy and 
higher rates of atrophy 
in AD-affected regions 
 
(Berti et al., 2011; 
Debette et al., 
2009; Honea et al., 
2011; Honea et al., 
2010) 
 
Brain Aβ PET PIB Decreased brain 
parenchyma Aβ levels 
 
(Mosconi et al., 
2010b) 
CSF Aβ CSF ELISA Aβ42/Aβ40 ratio 
decreased 
 
(Mosconi et al., 
2010a) 
CSF Isoprostanes Mass spectrometry Isoprostanes elevated 
 
(Mosconi et al., 
2010a) 
 
Memory 
performance 
Cognitive 
evaluation 
Among APOE4 
carriers, lower memory 
test scores 
 
(Debette et al., 
2009) 
COX activity Platelet 
mitochondria COX 
Vmax assay 
 
Reduced COX activity 
 
 
(Mosconi et al., 
2011) 
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Table 1. Effect of maternal influence on non-demented subject AD endophenotypes. 
Modified from (Silva et al., 2012b). 
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Figure 2. Generation of cybrid cell lines. Tumor or immortalized cell lines are grown in 
the presence of ethidium bromide, which effectively eliminates functional mtDNA to 
result in a ρ0 cell line. ρ0 cells are then fused with a patient’s platelets, which contain 
mitochondria, but not nuclei. This creates cytoplasmic hybrid (cybrid) cells that can be 
isolated and expanded. Differences in function between cell lines most likely arise 
through differences in their mtDNA.  
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further been observed that cybrid lines containing AD subject mitochondria/mtDNA 
overproduce oxygen radicals, accumulate Aβ, and have decreased ATP levels compared 
to control cybrid lines containing mtDNA from unaffected individuals (Cardoso et al., 
2004b; Khan et al., 2000; Swerdlow, 2007). Since three of the 13 COX subunits are 
encoded by mtDNA, this phenomenon suggests mtDNA differs between AD patients and 
control subjects, and supports the view that mtDNA contributes to the AD-associated 
COX activity reduction. Taken together, these results support hypotheses which place 
mitochondrial dysfunction at the center of AD pathogenesis (Swerdlow et al., 2010; 
Swerdlow & Khan, 2004, 2009; Swerdlow et al., 1997b). 
Oxidative stress is present systemically and in AD brains 
Reactive oxygen species (ROS) are a frequent by-product of electron leakage 
from the inner mitochondrial membrane during mitochondrial oxidative phosphorylation.  
Up to 4% of O2 used by mitochondria is converted to superoxide radical (Hansford et al., 
1997; Inoue et al., 2003; Markesbery & Lovell, 1998; Morten et al., 2006; Turrens & 
Boveris, 1980), and approximately 109 to 1011 ROS are produced per cell per day (Bonda 
et al., 2010; Feinendegen, 2002; Ji, 1999; Petersen et al., 2007). Under normal conditions, 
ROS are rapidly cleared to increasingly lesser reactive species by enzymes such as 
superoxide dismutase, catalase, and glutathione peroxidase (GPx). When mitochondria 
are perturbed, however, ROS production may exceed the cell’s ability to neutralize them, 
resulting in oxidative damage to the cell (Smith et al., 2000). Aging itself is associated 
with elevated ROS production by mitochondria (Ames et al., 1995; Shigenaga et al., 
1994), and accumulation of oxidative damage over time may contribute to the noted 
association between advancing age and AD.  
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Oxidative stress is thought to be an early manifestation of AD (Nunomura et al., 
2001). Studies of post-mortem AD brains indicate widespread oxidative damage. Four-
hydroxynonenal and acrolein, which are aldehydes produced by lipid peroxidation, and 
isoprostanes, which are pro-inflammatory products of arachidonic acid peroxidation, are 
significantly elevated in hippocampi from AD brains (Markesbery & Lovell, 1998; 
Pratico et al., 1998; Sayre et al., 1997; Singh et al., 2010).  This indicates excessive lipid 
oxidation occurs in the AD brain. In AD brains both nuclear and mitochondrial DNA and 
RNA also display evidence of oxidative damage (Gabbita et al., 1998; Mecocci et al., 
1994; Nunomura et al., 1999). Brains from individuals affected with AD further display 
increased protein oxidation, as evidenced by carbonyl-alterations of specific proteins 
(Castegna et al., 2002a; Castegna et al., 2002b; Smith et al., 1991; Sultana et al., 2010).  
Many studies suggest that oxidative damage is also present in individuals with 
mild cognitive impairment (MCI), a syndromic state that in many cases represents a very 
early AD clinical stage (Aluise et al., 2011; Butterfield et al., 2006b; Butterfield et al., 
2007; Keller et al., 2005; Lovell & Markesbery, 2008; Markesbery & Lovell, 2007; 
Pratico et al., 2002). In fact, studies suggest that levels of oxidative markers directly 
correlate with severity of cognitive impairment as well as symptomatic progression from 
MCI to AD (Ansari & Scheff, 2010; Keller et al., 2005).  
Extensive oxidative damage in AD brains likely has significant consequences for 
neurons, as oxidative modification of proteins and other molecular components can alter 
cell function (Butterfield et al., 1997; Lauderback et al., 2001; Subramaniam et al., 1997; 
Sultana & Butterfield, 2009). As a major source for ROS production, mitochondria are 
themselves at risk of acquiring oxidative damage. As discussed earlier, the activities of 
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certain mitochondrial enzymes including isocitrate dehydrogenase, pyruvate 
dehydrogenase complex, α-ketoglutarate dehydrogenase complex, and COX are 
significantly reduced in the AD brain (Aksenov et al., 1999; Bubber et al., 2005; 
Butterfield et al., 2006a; Gibson et al., 1998; Manczak et al., 2004; Yates et al., 1990). 
These enzyme impairments may represent a consequence or cause of ROS production or 
both. For instance, COX dysfunction might further elevate ROS production by stalling 
electron transfer (Barrett et al., 2004; Skulachev, 1996; Sullivan & Brown, 2005; Sullivan 
et al., 2004). Thus, dysfunctional mitochondria in AD may give rise to and perpetuate a 
vicious cycle of oxidant production in which impairment of one mitochondrial enzyme 
elevates ROS production, which in turn impairs the function of other mitochondrial 
enzymes, which in turn further increases ROS production (Bonda et al., 2010; Zhu et al., 
2004).  
Clearly, brains from individuals with AD undergo extensive oxidative damage 
throughout the disease process. Significant evidence suggests that oxidative damage in 
AD is not brain-limited, but is also present systemically in AD patients (Burns et al., 
2009). In fact, individuals with AD also experience systemic metabolic dysfunction in the 
form of metabolic syndrome, diabetes, weight loss, poor cardiorespiratory fitness, and 
sarcopenia (Burns et al., 2012; Burns et al., 2010; Giordano et al., 2007; Huang & Hood, 
2009; J et al., 2009; Mattson et al., 1999; Morris & Burns, 2012; Vidoni et al., 2012; 
Vidoni et al., 2011; Wolf-Klein & Silverstone, 1994). Thus, even though AD is best 
recognized by its significant impairment of cognition, the brain is not the only system 
affected.  
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One study evaluated the presence of oxidative stress in platelets and erythrocytes 
from normal controls and AD patients. This study found elevated oxidative stress 
markers in AD patients in the form of thiobarbituric acid-reactive substances, nitric oxide 
synthase activity, and Na,K-ATPase activity, suggesting that oxidative stress is present 
systemically in AD (Kawamoto et al., 2005). Another study found that reactive oxygen 
species are elevated in circulating neutrophils from AD patients (Vitte et al., 2004). 
Plasma from AD subjects shows significantly decreased levels of the antioxidants 
lycopene, lutein, and carotene when compared to plasma from control subjects, and 
leukocytes from AD patients display elevated levels of oxidized DNA (Mecocci et al., 
2002; Mecocci et al., 1998; Migliore et al., 2005; Morocz et al., 2002).   
Oxidative stress is also ubiquitous in patients with MCI, suggesting that the 
oxidative damage seen in AD is a continuation of the stress that is also present during 
MCI. Interestingly, many studies further suggest that between MCI and AD subjects, no 
major differences in oxidative stress markers such as malondialdehyde and oxidized 
glutathione exist (Baldeiras et al., 2008; Bermejo et al., 2008; Padurariu et al., 2010). 
Rather, these studies propose that the primary biochemical differences between MCI and 
AD lie in the levels and activity of antioxidants such as superoxide dismutase, glutathione 
peroxidase, and vitamin E. This suggests that a loss of one’s ability to compensate for 
oxidative stress may underlie or else serve as a marker of MCI-to-AD progression.  
Additional evidence suggests that oxidative stress markers may correlate with 
disease progression and severity in AD patients. Torres et al. recently found that plasma 
levels of malondialdehyde, a lipid peroxidation product, directly associate with impaired 
cognitive function in AD patients. The authors also found that the ratio of glutathione 
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reductase activity to glutathione peroxidase activity, which provides an indication of a 
cell’s antioxidant capacity, associates with cognitive function (Torres et al., 2011). 
Additionally, serum levels of the dietary antioxidant vitamin E relate to cognitive status 
(Baldeiras et al., 2008; Panza et al., 2010).   
Data such as these have encouraged investigators to attempt to develop peripheral 
AD diagnostic and biomarker tests (Burns et al., 2009; Pratico, 2005). While a definitive 
biomarker with adequate sensitivity and specificity remains to be identified, a plethora of 
data suggests that at least on a biochemical and molecular level, AD is a systemic 
disorder. 
Mitochondrial biomass and homeostasis in AD 
Because of their high energy demands, neurons are especially dependent on 
mitochondrial dynamics, and tightly control their mitochondrial mass (Santos et al., 
2010). When neurons accumulate dysfunctional mitochondria or experience increased 
metabolic or bioenergetic demands, they must pursue one or a combination of several 
strategies to ensure sustained function. One response includes autophagy, an important 
mechanism through which abnormal mitochondrial are decommissioned and eliminated. 
Fusion and fission events help traffic abnormal mitochondria toward autophagic 
processing and help maintain normal mitochondrial numbers throughout the neuron. 
Biogenesis produces new mitochondria and increases mitochondrial mass. Evidence 
suggests that cells tightly regulate mitochondrial fission, fusion, autophagy, and 
biogenesis in order to maintain a healthy mitochondrial population (Twig et al., 2008b).  
Mitochondrial autophagy in AD 
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Autophagy helps cells eliminate unnecessary cytoplasmic contents via phagosome 
formation and lysosomal degradation (Yang & Klionsky, 2011; Youle & Narendra, 
2011). In hepatic cells, inhibition of mitochondria by the antiretroviral drug efavirenz 
significantly upregulates mitochondrial autophagy, and ultimately appears to have a 
protective effect (Apostolova et al., 2011a, 2011b) . Findings like these support the view 
that autophagic elimination of dysfunctional mitochondria under some conditions could 
prove physiologically advantageous. This may have important implications for AD, since 
AD is characterized by the presence of dysfunctional mitochondria.  
In 2001, Hirai et al. reported that when mtDNA contained within phagocytized 
mitochondria are specifically accounted for, AD subject hippocampal neurons can 
actually contain elevated levels of mtDNA (Hirai et al., 2001). This finding suggests that 
mitochondrial autophagy rates are increased in AD. Also, in AD brains, other 
mitochondrial components such as COX and lipoic acid, a cofactor utilized by pyruvate 
dehydrogenase and α-ketoglutarate dehydrogenase, concentrate within autophagosomes 
(Hirai et al., 2001; Moreira et al., 2007). Ultrastructural analysis of dystrophic neurites in 
AD brains indicates that most organelles present are autophagosomes, further supporting 
the view that autophagy is increased in AD neurites (Nixon et al., 2005). In healthy 
neurons, by contrast, autophagosome accumulation is rarely observed (Boland et al., 
2008; Nixon & Yang, 2011).  
Some studies find that autophagic fluxes are impaired in AD (Cataldo et al., 1995; 
Nixon & Yang, 2011), which could potentially account for increased numbers of 
autophagosomes in AD neurons. Whether increased mitochondrial autophagy in AD is 
due to a break-down in autophagy pathways or increased flux through functioning 
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autophagy pathways remains to be seen. The need to dispose of elevated numbers of 
dysfunctional mitochondria could conceivably lead to either or both possibilities.   
Several pathways that monitor cell energy status link mitochondria with 
autophagy and permit mitochondrial function to regulate autophagy activity. Nutrient 
deprivation and decreased bioenergetic capacity of cells inhibit cytosolic mammalian 
target of rapamycin (mTOR) signaling (Noda & Ohsumi, 1998; Scott et al., 2004; Tee et 
al., 2005). Inhibition of mTOR allows the initiation of autophagosome formation (Crespo 
et al., 2005), thus promoting autophagy. Decreased mitochondrial function can also 
increase cell AMP/ATP ratios. Elevating AMP relative to ATP activates AMP kinase 
(AMPK), which modifies a wide range of cellular activities in order to maintain energy 
homeostasis (Carling et al., 1994; Hardie & Hawley, 2001; Mihaylova & Shaw, 2011).  
Interestingly, AMPK can inhibit the mTOR signaling pathway, and thus upregulate 
autophagy (Meley et al., 2006), suggesting that high cellular AMP levels due to 
mitochondrial dysfunction may activate autophagic clearance of mitochondria. Indeed, 
one study found that in AD patients, lymphocyte mTOR levels directly correlate with 
cognitive decline (Paccalin et al., 2006). This study is consistent with the view that 
systemic mitochondrial deficits occur in AD, and further suggests a potential role for 
perturbed mTOR signaling-autophagy relationships in AD.  
Mitochondrial fission and fusion 
Mitochondrial fission and fusion are necessary for proper mitochondrial function 
(Santos et al., 2010). For example, inhibition of fusion by genetic knockout of mitofusin 
2 (Mfn2) causes severe mitochondrial dysfunction that drives neuronal degeneration 
(Chen et al., 2007).   
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Impaired fission also interferes with the cell’s ability to target dysfunctional 
mitochondria for autophagic removal. Fission divides a dysfunctional mitochondrion into 
two unequal daughter mitochondria, one with seemingly normal mitochondrial markers 
and the other with dysfunctional markers. The dysfunctional daughter unit is then 
packaged for autophagy, while the healthy unit is free to undergo fusion (Twig et al., 
2008a).     
In AD, fission seems to be particularly perturbed (Manczak et al., 2011; Wang et 
al., 2008a; Wang et al., 2009; Wang et al., 2008b). This phenomenon is not brain limited, 
but appears to also apply to fibroblasts from sporadic AD subjects (Wang et al., 2008a).  
Wang et al. reported that in 19% of fibroblasts from AD patients, mitochondria were 
excessively localized to the perinuclear region and were dramatically elongated. 
Additionally, it was found that dynamin-related protein 1 (Drp1), a protein that plays a 
major role in mitochondrial fission, was significantly decreased and that experimental 
over-expression of Drp1 in these cells rescued the abnormal mitochondrial morphology.  
In this study, the exaggerated mitochondrial perinuclear distribution further emphasizes 
that fission-fusion dynamics influence mitochondrial transport, since abnormally sized 
mitochondria may distribute throughout the cell differently than normal mitochondria.  
In possible contrast to the Wang et al. study, Manczak et al. more recently 
reported Drp1 mRNA and protein were increased in AD subject autopsy brains (Manczak 
et al., 2011) . However, this group also described a significant increase in Fis1, a 
mitochondrial fission protein, and a decrease in the Mfn1 and Mfn2 fusion proteins. 
These findings further support the case that mitochondrial fission and fusion are disrupted 
in AD. 
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Mitochondrial biogenesis 
Mitochondrial biogenesis is the process by which cells generate new mitochondria 
and, if necessary, increase mitochondrial mass. This process involves coordinated 
expression of proteins encoded by nuclear and mitochondrial DNA. To accomplish this, 
the transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator 1α 
(PGC1α) coordinates mitochondrial biogenesis in at least some tissues such as muscle, 
heart, liver, and pancreas via co-activation of various transcription factors (Finck et al., 
2006; Finck & Kelly, 2006; Lehman et al., 2000; Lin et al., 2002a; Onyango et al., 
2010b; Rhee et al., 2003).  
PGC1α is regulated by several metabolism-responsive elements. Sirtuin 1, which 
is activated by NAD+, de-acetylates PGC1α protein. This is an activating de-acetylation 
that helps to increase mitochondrial biogenesis (Lagouge et al., 2006; Nemoto et al., 
2005). AMP kinase (AMPK), which is activated by elevated AMP/ATP ratios, can 
phosphorylate and thus directly activate PGC1α (Jager et al., 2007; Reznick & Shulman, 
2006). For example, AMPK activation of PGC1α in rat visual cortical neurons increases 
mitochondrial mass (Yu & Yang, 2010). AMPK can also modulate the activities of other 
proteins, such as mTOR and forkhead box containing protein O (FOXO), to further affect 
PGC1α activity (Cunningham et al., 2007; Daitoku et al., 2003; Greer et al., 2009; Nakae 
et al., 2008a; Nakae et al., 2008b).  
PGC1α mRNA and protein levels are reduced in AD subject brains (Qin et al., 
2009; Sheng et al., in press; Swerdlow, 2011a). Even if PGC1α changes represent a 
consequence as opposed to cause of AD pathology, PGC1α remains an attractive target 
for therapeutic intervention.  Whether mitochondrial mass changes in AD constitute an 
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upstream or downstream physiologic event, it is reasonable to postulate that increasing 
mitochondrial mass may alleviate bioenergetics-related stress in the AD brain. 
Mitochondrial transport 
Evidence suggests that mitochondria can be rapidly transported to areas of high 
bioenergetic demand as required by the neuron (Hollenbeck & Saxton, 2005; MacAskill 
et al., 2010). This mitochondrial transport appears to be important for the development, 
stability, and function of synapses and dendritic spines (Li et al., 2004; Mattson et al., 
2008), and impaired mitochondrial trafficking has been implicated in a number of 
neurodegenerative disorders such as Huntington’s disease (Reddy & Shirendeb, 2011), 
Parkinson’s disease (Sterky et al., 2011), and amyotrophic lateral sclerosis (De Vos et al., 
2007). Altered mitochondrial transport may also play a role in AD. One study found that 
mitochondrial transport in AD patient brains was decreased compared to control brains 
(Dai et al., 2002). Trimmer and Borland showed that the transport of fluorescently-
labeled mitochondria in cybrids generated from AD patients is significantly reduced 
compared to control cybrids, suggesting that mitochondrial transport may be impaired in 
AD (Trimmer & Borland, 2005). Mitochondrial transport is also altered in mouse models 
of AD (Calkins et al., 2011; Massaad et al., 2010; Pigino et al., 2003) and in cell cultures 
treated with Aβ (Calkins & Reddy, 2011). These studies together argue that impaired 
mitochondrial transport impacts the pathogenesis of AD.  
Apoptosis in AD 
AD brains experience significant neuron loss, which likely contributes to an 
affected person’s cognitive decline (Shimohama, 2000; Terry et al., 1991). While some 
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neuron loss is due to necrosis, the rest is likely due to or else invokes aspects of 
apoptosis, a tightly-regulated form of programmed cell death (Barinaga, 1998). 
DNA fragmentation, as assessed by TUNEL staining, is a common hallmark of 
apoptosis. Neurons in AD brains display increased DNA fragmentation compared to 
control brains (Anderson et al., 1996; Broe et al., 2001; Colurso et al., 2003; Lassmann et 
al., 1995; Li et al., 1997; Smale et al., 1995; Su et al., 1994; Troncoso et al., 1996). Many 
of these studies also reveal morphologic changes associated with apoptosis including 
abnormal chromatin, an absence of nucleoli, and shrunken or irregular cell shapes 
(Shimohama, 2000). Other studies note an increased proportion of apoptotic to normal 
neurons (Broe et al., 2001). DNA fragmentation in AD cell death surveys also associates 
with expression of c-Jun, which is typical of apoptotic neurons (Behl, 2000), and caspase 
proteins (Masliah et al., 1998). These studies suggest apoptosis pathways are activated in 
the AD brain.  
Correspondingly, AD brains express significantly higher levels of the pro-
apoptotic proteins Bak and Bad (Kitamura et al., 1998; Shimohama, 2000). Other studies 
suggest that AD brains display elevated pro-apoptotic Bax (Su et al., 1997). Caspases 3 
and 6, which are apoptosis “executioner” caspases, are increased in AD brains (Avila, 
2010; Guo et al., 2004; Masliah et al., 1998; Rohn et al., 2001b; Selznick et al., 1999; 
Stadelmann et al., 1999), as are the initiator caspases 8 and 9 (Albrecht et al., 2007; Rohn 
& Head, 2009; Rohn et al., 2001a; Rohn et al., 2002).  
Further evidence that apoptotic events are more frequent in AD brains than in 
age-matched controls comes from experiments evaluating the presence of the cytoskeletal 
spectrin protein fodrin, which is cleaved early in the apoptotic cascade by caspases 
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(Cribbs et al., 2004). Brains from AD patients display increased amounts of fodrin 
cleavage products (Ayala-Grosso et al., 2006; Masliah et al., 1991; Masliah et al., 1990).  
Interestingly, evidence suggests that the pro-apoptotic shifts seen in AD subjects 
are not brain-limited. One study found that lymphocytes from AD patients were pre-
disposed to apoptosis (Eckert et al., 2001). Another study reported increased fodrin 
cleavage in fibroblasts from AD patients (Peterson et al., 1991).  
In summary, substantial data suggest that apoptosis is elevated in AD. This is not 
surprising given the other molecular and biochemical perturbations observed in this 
disease. For example, oxidative stress can predispose cells to apoptosis (Buttke & 
Sandstrom, 1994; Ray et al., 2012; Sandstrom et al., 1994). The prolific oxidative 
damage present in AD may, therefore, contribute to increased apoptosis. 
Altered metabolic status and impaired mitochondrial function may affect Aβ processing 
Accumulating data indicate mitochondrial bioenergetics, bioenergetic 
homeostasis, and probably brain metabolism in general affect APP processing (Brody et 
al., 2008; Gabuzda et al., 1994; Gasparini et al., 1997; Kang et al., 2009; Khan et al., 
2000; Webster et al., 1998). To better understand this phenomenon, it is worth 
considering how mitochondrial function impacts certain cell signaling pathways.  
NAD+/NADH ratio and the cell redox status 
Mitochondria oxidize reduced NADH to NAD+.  This activity is integrated into 
other cell bioenergetics-related pathways, such as glycolysis, which requires the presence 
of NAD+ to proceed. The primary role of complex I (NADH:ubiquinone oxidoreductase) 
in the ETC is to accept high energy electrons from NADH, which is produced during 
glycolysis, the tricarboxylic acid cycle, or other specific redox reactions. A malate-
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aspartate shuttle allows the transfer of NADH reducing equivalents from the cytosol and 
into the mitochondrial matrix. When mitochondria are inhibited experimentally or 
functioning suboptimally, the ratio of NAD+/NADH within the cell can substantially 
decrease (Braidy et al., 2011; Schuchmann et al., 2001; Stefanatos & Sanz, 2011). 
Conversely, cells with relatively healthy mitochondria may have a high NAD+/NADH 
ratio. NAD+ is utilized by and activates other enzymes, including the sirtuin (silent 
mating type information regulation two homolog) family of proteins. Sirtuins are 
increasingly believed to play roles in neuroprotection and longevity, and sirtuins may 
represent AD therapeutic targets (Guarente, 2011; Lombard et al., 2011; Rahman & 
Islam, 2011; Zhang et al., 2011a, 2011b).  
Sirtuin 1 protein, which is encoded by the gene SIRT1, may regulate APP 
processing. In 2010, Donmez et al. showed that sirtuin 1 upregulates expression of 
ADAM10, which encodes an α-secretase (Donmez et al., 2010). Specifically, the authors 
showed that in a transgenic mouse model of AD, co-transgenic overexpression of SIRT1 
resulted in a significant reduction of amyloid plaques and Aβ42 levels. Brain-specific 
deletion of SIRT1 induced significant mortality at age 3-5 months in mice transgenic for 
mutant human APP and presenilin transgenes. It was further demonstrated that SIRT1 
overexpression resulted in significantly higher α-secretase protein levels, which 
coincided with increased levels of α-secretase cleavage products. From a mechanistic 
perspective, sirtuin 1 seemed to interact with and deacetylate the retinoic acid receptor β 
to increase ADAM10 transcription, as the ADAM10 promoter contains a retinoic acid 
receptor element.  
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By shifting the cell NAD+/NADH redox balance towards a more reduced state, 
mitochondrial dysfunction could reduce the amount of NAD+ that is available to sirtuin 
1. This in turn could reduce α-secretase levels and divert APP processing towards its β-
secretase derived Aβ product.  
Oxidative stress 
Oxidative stress is believed to represent an early manifestation of AD pathology 
(Nunomura et al., 2001). Numerous studies indicate that AD brains have oxidized RNA, 
nuclear and mtDNA, lipids, and proteins (Gabbita et al., 1998; Mecocci et al., 1994; 
Nunomura et al., 1999; Sayre et al., 1997; Smith et al., 1991). Mitochondria are the 
primary source of intracellular ROS, and elevated ROS correlates with mitochondrial 
dysfunction (Shigenaga et al., 1994). Depending on cell type and intracellular 
localization, ROS can have a vast array of functions, some beneficial and necessary, 
others detrimental and pathological (Finkel, 2011). Considerable data implicate a 
mechanistically relevant role for ROS in AD.  In particular, evidence suggests elevated 
ROS upregulate Aβ production (Tamagno et al., 2002).  
Studies in COS, PC12, and neuroglioma cell lines indicate that perturbation of 
mitochondrial function with sodium azide, oligomycin, or carbonyl cyanide m-
chlorophenylhydrazone shifts APP processing away from its α-secretase cleavage, thus 
decreasing soluble APP derivatives and likely promoting the amyloidogenic beta 
secretase-mediated cleavage of APP (Gabuzda et al., 1994; Gasparini et al., 1997; 
Webster et al., 1998).  In one study, glutathione supplementation restored soluble APP 
processing, suggesting oxidative stress was to some degree responsible for diverting APP 
processing away from the α-secretase cut (Gasparini et al., 1997).  
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Figure 3. Role of ROS in APP processing. A. Excess ROS are produced by dysfunctional 
mitochondria. B. ROS oxidizes thioredoxin, releasing it from ASK1. C. ASK1 causes 
JNK activation. D. Alternatively, ROS oxidizes GST, releasing JNK. E. Activated JNK 
deacetylates histones and demethylates APP, BACE, and presenilin gene promoters, 
which leads to increased Aβ production 
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The identification of signaling molecules sensitive to ROS has helped to further 
implicate a role for ROS in driving amyloidosis (Figure 3). For example, a 1998 report by 
Saitoh et al. reported the redox homeostatic protein thioredoxin binds to and inactivates 
the mitogen activator protein kinase kinase kinase (MAPKKK) ASK1 (apoptosis signal-
regulating kinase) (Saitoh et al., 1998). ROS can directly oxidize thioredoxin, and when 
this occurs thioredoxin dissociates from ASK1 (Finkel, 2011; Gotoh & Cooper, 1998; 
Saitoh et al., 1998; Shen & Liu, 2006). Free ASK1 can undergo phosphorylation, and  
subsequently activate its downstream targets. One of these targets includes c-Jun N-
terminal kinase (JNK) (Filomeni et al., 2003; Filomeni et al., 2005).  
In addition to its upregulation by ASK1, ROS may activate JNK through other 
mechanisms (Figure 3). Adler et al. showed that glutathione S-transferase (GST) 
associates with and inhibits JNK (Adler et al., 1999a; Adler et al., 1999b). This may 
partly explain why, in the absence of oxidative stress, JNK activity tends to remain low. 
In the presence of oxidative stress, however, GST is oxidized.  Oxidized GST no longer 
binds JNK, thus preventing GST-mediated JNK inhibition.  
Recently, Guo et al. showed that anisomycin-induced JNK activation significantly 
increased Aβ production in SH-SY5Y neuroblastoma cells (Guo et al., 2011). These 
investigators further showed that activation of JNK caused upregulation of APP, β-site 
APP cleaving enzyme 1 (BACE1), and the presenilin 1 gene through demethylation of 
their respective promoters and histone deacetylation.  These effects would collectively be 
expected to increase Aβ production. Studies such as these provide additional insight into 
how a primary mitochondrial defect might drive amyloidosis.  
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Summary 
While the bulk of this Introduction has focused on the role of mitochondrial 
metabolism in Alzheimer’s disease, there is considerable evidence that mitochondrial 
dysfunction lies at the heart of most neurodegenerative disorders including Parkinson’s 
disease and amyotrophic lateral sclerosis (Beal, 1998; De Vos et al., 2007; Pacelli et al., 
2011; Sheehan et al., 1997a; Sheehan et al., 1997b; Shin et al., 2011; Swerdlow et al., 
1996; Trimmer et al., 2000). Thus, we believe that a better understanding of the 
intricacies of mitochondrial function will benefit a host of neurological disorders.  
The goals of this dissertation can be described by four aims: 1) to better 
understand the interplay of mitochondrial and nuclear signals that govern mitochondrial 
function; 2) to evaluate the role of dietary intervention on markers of mitochondrial mass 
and on metabolic status in mice; 3) to study the role of mitochondrial DNA in 
neurodegenerative diseases and aging; and 4) to better understand the molecular 
mechanisms involved in a non-pathological, physiological neurodegenerative process. In 
Chapter 2, we will describe a study in which we utilized a neuroblastoma cell line 
without mtDNA to evaluate how mitochondria are controlled by nuclear and metabolic 
cues. In Chapter 3, we establish the metabolic and mitochondrial effects of a ketogenic 
diet on mouse brains. In Chapter 4, we discuss the generation of cybrid cell lines to 
evaluate the role of mitochondrial DNA in neurodegenerative diseases and aging. And, in 
Chapter 5, we evaluate the role of the pan-neurotrophin receptor p75NTR in the 
physiological cyclical degeneration of sympathetic nerves in mouse uteri.  
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Chapter II: Retrograde signaling in mtDNA-depleted neuroblastoma cells attempt 
to upregulate mitochondrial respiration while limiting mitochondrial mass 
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INTRODUCTION 
Cells depleted of mtDNA (ρ0 cells) have generated insight into mitochondrial 
retrograde signaling processes and have been used to study human disorders of reduced 
mtDNA content such as mitochondrial myopathies, neurodegenerative diseases, drug-
induced mtDNA-depletion, mtDNA depletion syndromes, and mitochondrial mechanisms 
of oncogenesis (Cavalli et al., 1997; Hayashi et al., 1992; Larsson et al., 1994; Magda et 
al., 2008; Marusich et al., 1997; Moraes et al., 1991; Poulton et al., 1994; Spelbrink et al., 
1998; Taanman et al., 1997). Other groups have utilized ρ0 cells to investigate the role of 
mitochondrial respiration in cells (Masgras et al., 2012; Qian & Van Houten, 2010; Shen 
et al., 2003).  
Because mtDNA encodes key respiratory chain subunits, cells without mtDNA 
are aerobically incompetent (Magda et al., 2008; Shen et al., 2003). Generated by chronic 
exposure to low concentrations of ethidium bromide or dideoxycytosine (King & Attardi, 
1996; Nelson et al., 1997), ρ0 cells are completely reliant upon glycolysis for ATP 
generation (King & Attardi, 1989) and have abnormal mitochondrial morphology. ρ0 
mitochondria retain basic structural components encoded by nuclear chromosomes; 
however, cristae and overall morphology of mitochondria in ρ0 cells are significantly 
abnormal: mitochondrial shape is swollen and fragmented, the interconnected reticulum 
of mitochondria within the cell is significantly disrupted, and cristae are poorly 
developed and tubular in structure (Ferraresi et al., 2008; Gilkerson et al., 2000; Herzberg 
et al., 1993; Marusich et al., 1997; Mercy et al., 2005). ρ0 cells continue to express 
nuclear-encoded mitochondrial elements such as citrate synthase, cytochrome c, porins, 
complex II, cytochrome c oxidase subunit IV, and apoptotic machinery (Ferraresi et al., 
33 
2008; Herzberg et al., 1993; Li et al., 1995; Marchetti et al., 1996; Marusich et al., 1997; 
Mueller et al., 2012). Interestingly, contradictory data exist in the literature regarding ρ0 
cell maintenance of the mitochondrial membrane potential (ΔΨm); some studies report 
that ΔΨm is unaffected in ρ0 cells (Ferraresi et al., 2008; Marchetti et al., 1996), while 
others observed a reduction in ΔΨm (Mercy et al., 2005; Moro et al., 2008). Additionally, 
some studies have found that ρ0 cells have a lower threshold for apoptosis (Liu et al., 
2004). 
Coordination of mitochondrial protein expression is a complex and delicate 
process that is governed by a number of cues: mitochondrial, nuclear, environmental, and 
metabolic. The key players in mitochondrial protein transcription are nuclear respiratory 
factors 1 and 2 (NRF1, NRF2), transcription factor A mitochondrial (TFAM), and 
peroxisome proliferator activated receptor gamma coactivator 1α (PGC1α). In general, 
NRF1 and NRF2 regulate expression of nuclear-encoded genes for mitochondrial 
respiration (Dhar et al., 2008; Evans & Scarpulla, 1989, 1990; Ongwijitwat et al., 2006; 
Scarpulla, 2011b; Virbasius et al., 1993). TFAM regulates transcription of mitochondrial 
genes from the mitochondrial chromosome and assists in mtDNA maintenance (Fisher & 
Clayton, 1988; Kaufman et al., 2007; Larsson et al., 1998). PGC1α is a transcriptional 
cofactor that participates in a number of transcription activation events related to 
mitochondrial function especially mitochondrial biogenesis (Puigserver et al., 1998; 
Scarpulla, 2011a; Uldry et al., 2006; Wagatsuma et al., 2011; Wu et al., 1999). 
Additionally, PGC1α can modulate the expression and activities of the other respiratory 
factors NRF1, NRF2, and TFAM (Baar, 2004; Michael et al., 2001; Scarpulla, 2006; Wu 
et al., 1999). Two other PGC1α-like coactivators have been identified that also appear to 
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regulate these mitochondrial transcription factors: PGC1β and PGC1α-related coactivator 
(PRC) (Andersson & Scarpulla, 2001; Gleyzer et al., 2005; Shao et al., 2010; Vercauteren 
et al., 2008; Vercauteren et al., 2006). A handful of studies have studied mitochondrial 
transcription factors in ρ0 cells. Some have identified a reduction in TFAM (Larsson et 
al., 1994; Mercy et al., 2005; Mueller et al., 2012; Poulton et al., 1994; Seidel-Rogol & 
Shadel, 2002). Others have found an elevation in TFAM and NRF1 (Miranda et al., 
1999). Clearly, regulation of mitochondrial function is a complex process.  
The goal of this study is to use mtDNA-depleted SH-SY5Y cells to better 
understand the interplay between respiratory transcription factors and metabolic cues and 
to better characterize mitochondrial retrograde signaling pathways that may result in 
elevated mitochondrial proteins in neuronal-like (neuroblastoma) cell lines. We found 
that SY5Y ρ0 cells significantly downregulate PGC1α, and that this downregulation is 
associated with a number of retrograde signaling changes including dramatic 
upregulation of the newly identified PGC1α transcription inhibitor ZNF746/PARIS.  
 
METHODS 
Cell Culture 
SH-SY5Y ρ0 cells were generated previously by chronic exposure to low 
concentrations of ethidium bromide (Miller et al., 1996). SH-SY5Y and SH-SY5Y ρ0 
cells were cultured in DMEM high glucose (Gibco #11965) supplemented with 10% FBS 
and 1% penicillin/streptomycin. Because ρ0 cells are auxotrophic for pyruvate and 
uridine, growth media for ρ0 was additionally supplemented with 100µg/mL sodium 
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pyruvate and 50µg/mL uridine. For experimental procedures, cells were plated in 60mm 
tissue culture dishes and grown to ~95% confluency prior to harvest.  
ADP/ATP and NAD+/NADH assay 
For ADP/ATP assay, cells were plated in a clear-bottomed 96-well cell culture 
plate at a density of 105 cells per well. 12 hours after plating, the EnzyLight ADP/ATP 
ratio assay (BioAssay Systems #ELDT-100) was performed according to manufacturer’s 
instructions. For NAD+/NADH assay, cells were plated on 60mm dishes at a density of 
3x106 cells per dish. 24 hours after plating, cells were harvested via trypsinization, 
washed, pelleted and frozen at -80°C. EnzyFluo NAD/NADH assay (BioAssay Systems 
#EFND-100) was performed according to manufacturer’s instructions. 
RNA Isolation and Gene Expression/qRT-PCR 
RNA was isolated from cells using TRI reagent (Sigma-Aldrich #T9424) 
following standard protocol. Briefly, cells extracts were collected using TRI reagent, 
RNA separated using chloroform, precipitated with isopropanol, and washed with 75% 
ethanol. cDNA was generated using an RT-PCR cDNA kit, which primes cDNA with 
random primers (Applied Biosystems #4368814). qPCR reactions were performed on an 
Applied Biosystems StepOne Plus 96-well Real Time PCR System or Applied 
Biosystems Prism 7900HT Sequence Detection System using Bio-Rad iTaq Master Mix 
(Bio-Rad #172-5131) and Applied Biosystems TaqMan gene expression primers: PGC1α 
(Hs01016719_m1), PGC1β (Hs00991677_m1), PRC (Hs00209379_m1), 
ZNF746/PARIS (Hs00978838_m1), NRF1 (Hs00192316_m1), NRF2 
(Hs01022016_m1), TFAM (Hs00273372_s1). GAPDH (Hs02758991_g1) was used as a 
loading control.  
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Protein Extraction and Western Blot 
Cell lysates were generated using M-PER mammalian protein extraction reagent 
(Thermo Pierce #78503) or NE-PER nuclear and cytoplasmic extraction buffer (Thermo 
Pierce #78835) per manufacturer’s instructions. After quantification of total protein using 
DC assay (Bio-Rad #500-0112), samples were subjected to SDS-PAGE electrophoresis 
(Bio-Rad #567-1084, #567-1085) and transferred to nitrocellulose membrane (Whatman 
Protran #10401196). Blots were blocked in 5% BSA (for antibodies to phosphorylated 
proteins) or 5% milk in PBST for 1hr, then incubated in primary antibody overnight, 
washed three times in PBST, secondary antibody for 1 hour, and then washed three times 
in PBST. Antibodies used are described in Table 1. Bands were visualized using 
SuperSignal West Femto Substrate (Thermo Pierce #34096) on a ChemiDoc XRS system 
(Bio-Rad).  
 
RESULTS 
SY5Y ρ0 cells operate with a higher energy deficit and impaired redox capacity 
compared to SY5Y cells 
Without the key electron transport chain subunits encoded by mtDNA, ρ0 cells are 
unable to further oxidize pyruvate produced by glycolysis. Thus, we hypothesized that, 
under the same conditions, ρ0 cells would have lower energy reserves than SY5Y cells. 
Using an ADP/ATP assay kit, we found that ρ0 cells had a 20% higher ADP/ATP ratio 
than SY5Y cells (Figure 1A). This finding suggests that the ability of ρ0 cells to 
adequately replenish ATP stores is impaired compared to SY5Y cells. Next, we wanted 
to investigate cell signaling molecules that might be activated during energy deficits. 
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Because AMPK can be activated in conditions of high AMP/ATP ratios, we evaluated the 
phosphorylation status of AMPK. Western blot analysis revealed that ρ0 cells have 2.4-
fold higher phosphorylation of AMPK than SY5Y cells (Figure 2).  
As another molecular sensor of energy status, SIRT1 is a histone deacetylase that 
can be activated by elevated NAD+/NADH ratios, making it keenly situated to enhance 
transcription of metabolic and mitochondrial genes in times of metabolic duress. We 
performed an NAD+/NADH ratio assay on SY5Y and ρ0 cells, and discovered that ρ0 
cells have a significantly lower NAD+/NADH ratio (Figure 1B), suggesting that ρ0 cells 
operate with an altered redox  
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Antibody Name Dilution Source Catalog # 
Akt 1:1000 Cell Signaling 4691 
Phospho-Akt (Thr308) 1:2000 Cell Signaling 2965 
AMPK 1:1000 Cell Signaling 2603 
Phospho-AMPK (Thr172) 1:1000 Cell Signaling 2531 
Cytochrome oxidase 
subunit IV 1:1000 Cell Signaling 4850 
CREB 1:500 Santa Cruz sc-25785 
Phospho-CREB 1:2000 Millipore 06-519 
Pan-CRTC 1:1000 Millipore ST-1098 
GAPDH 1:2000 Cell Signaling 2118 
GSK-3β 1:1000 Cell Signaling 9315 
Phospho-GSK3β (Ser9) 1:1000 Cell Signaling 5558 
HDAC1 1:1000 Thermo Pierce PA1-860 
mTOR 1:1000 Cell Signaling 2983 
Phospho-mTOR (Ser2448) 1:1000 Cell Signaling 5536 
NRF-1 1:1000 Santa Cruz Biotechnology sc-33771 
NRF-2 1:1000 AbCam Ab22838 
p70 S6 Kinase 1:1000 Cell Signaling 2708 
Phospho-p70 S6 Kinase 
(Thr389) 1:1000 Cell Signaling 9234 
SIRT1 1:1000 Cell Signaling 2496 
Phospho-SIRT1 1:1000 Cell Signaling 2314 
TFAM 1:1000 Aviva Biosystems ARP31400_P050 
Tom20 1:500 Santa Cruz Biotechnology sc-136211 
ZNF746/PARIS 1:1000 NeuroMab Facility Clone N196/16 
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Table 1: Summary of antibodies used in experiment.  
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Figure 1. A. ADP/ATP assay indicates that ρ0 cells have a higher ADP/ATP ratio than 
SY5Y cells. Error bars represent standard deviation, *p<0.05 (student’s two-tailed t-test). 
B. NAD+/NADH assay reveals that ρ0 cells have a lower NAD+/NADH ratio than SY5Y 
cells. Error bars represent standard error of the mean, *p<0.05 (student’s two-tailed t-
test). 
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Figure 2. Phosphorylation of AMPK is significantly elevated in ρ0 cells. Error bars 
represent standard deviation, *p<0.001 (student’s two-tailed t-test). 
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capacity compared to SY5Y cells. Interestingly, we found that both phosphorylation of 
SIRT1 and total SIRT1 protein were decreased in ρ0 compared to SY5Y (Figure 3). This 
is consistent with the finding that NAD+/NADH ratio is decreased in ρ0 cells, and 
suggests that SIRT1 is both inactivated and downregulated in ρ0 cells.  
SY5Y ρ0 cells have higher Akt signaling than SY5Y cells 
Akt signaling is thought to promote anaerobic cell metabolism, and may 
downregulate mitochondrial function by inhibiting the mitochondrial master regulator 
PGC1α (Cheng et al., 2010; Puigserver et al., 2003). To evaluate Akt signaling in SY5Y 
cells and ρ0 cells, we examined the phosphorylation of Akt at serine 473 via Western 
blot. We found that in basal growth conditions, SY5Y ρ0 cells have 3.2-fold higher 
cytoplasmic phosphorylated Akt than SY5Y cells and 2.7-fold higher nuclear 
phosphorylated Akt (Figure 4A). To ensure that this finding corresponds to a functional 
increase in Akt activity, we evaluated the phosphorylation status of Akt’s downstream 
effector GSK3β at serine 9. Western blot further revealed that phosphorylation of GSK3β 
at serine 9 is significantly increased 2.5-fold in ρ0 cells compared to SY5Y (Figure 4B), 
suggesting that Akt activity is enhanced in these mtDNA-less cell lines.  
mTOR signaling is affected by mtDNA depletion 
Next, we evaluated the mammalian target of rapamaycin (mTOR) signaling in ρ0 
cells. Integration of signals detecting nutrient status such as AMPK and Akt determines 
which complex mTOR will participate in—mTORC1 or mTORC2. When complexed 
with Raptor, mTOR comprises the catalytic unit of the mTORC1 complex (Laplante & 
Sabatini, 2009), and activated mTORC1 can increase transcription and activity of PGC1α 
(Cunningham et al., 2007). Western blot revealed that phosphorylation of mTOR at  
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Figure 3. Phosphorylation of SIRT1 is significantly decreased in ρ0 cells, as is total 
SIRT1 protein. Error bars represent standard deviation, *p<0.05, **p<0.001 (student’s 
two-tailed t-test). 
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Figure 4. A. Western blot of nuclear and cytoplasmic extracts of SY5Y and ρ0 cells 
reveal that phosphorylation of Akt at serine 473 is significantly increased in both 
compartments in ρ0 cells compared to SY5Y. B. Analysis of phosphorylated GSK3β in 
cytoplasmic compartment of SY5Y and ρ0 cells via western blot indicated that GSK3β 
phosphorylation is increased in ρ0 cells compared to SY5Y. Error bars represent standard 
deviation, *p<0.001 (student’s two-tailed t-test). 
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Ser2448 was significantly reduced in ρ0 cells (Figure 5). To ensure that this decreased 
mTOR phosphorylation corresponds to a decrease in mTORC1 activity (Chiang & 
Abraham, 2005), we evaluated levels of its downstream effector p70 S6 kinase (Holz & 
Blenis, 2005). Western blot indicated that phosphorylation of p70 S6 kinase was 
significantly reduced in ρ0 cells (Figure 5C), suggesting that reduced phosphorylation of 
mTOR at Ser2448 corresponds to reduced mTORC1 activity, and that mTORC1 activity 
in ρ0 cells is reduced compared to SY5Y (Peterson et al., 2000). This is consistent with 
our finding of elevated phosphorylation of AMPK, as pAMPK can inhibit mTORC1 
either via inhibition of Raptor or by activating mTORC1’s inhibitor TSC2 (Gwinn et al., 
2008; Hardie, 2008; Inoki et al., 2003a; Inoki et al., 2003b). One of activated mTORC1’s 
targets is translation of the purported master regulator of mitochondria PGC1α, thus 
reduced mTORC1 activity may correspond to decreased mitochondria.  
SY5Y ρ0 cells minimize maintenance of non-functional mitochondria  
Without mtDNA-encoded mitochondrial respiratory chain (MRC) subunits, the MRC as a 
whole is unable to catalytically convert high energy electrons into an intermembrane 
space proton gradient and again into generation of ATP from ADP by complex V. 
Despite the absence of mtDNA, ρ0 cells contain mitochondrial structures. These 
mitochondrial structures likely continue to serve a role in ρ0 apoptotic machinery, and as 
such must maintain a suitable membrane potential. Thus, because ρ0 mitochondria are 
non-respiratory and are unable to maintain their own membrane potential via electron 
transport through the MRC, the ρ0 cell itself must maintain the structural elements of its 
mitochondrial mass as well as its membrane potential. The energy required to maintain 
this potential must therefore be generated glycolytically. In a cell which relies so heavily  
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Figure 5. A. Western blots of mTOR and p70 S6 kinase. B. Phosphorylation of mTOR at 
Ser2448 was reduced by 43% in ρ0 cells compared to SY5Y. C. Phosphorylation of p70 
S6 kinase was reduced by 89% in ρ0 cells. 
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on glycolysis for its ATP and NADH production, this may prove to be an energetically 
difficult task for ρ0 cells, making these dysfunctional mitochondria an energetic liability.  
To evaluate the cells’ maintenance of dysfunctional, non-respiratory, non-
metabolic mitochondria, we first evaluated mitochondrial mass by examining levels of 
the nuclear-encoded mitochondrial protein cytochrome oxidase subunit IV (COXIV). 
Western blot showed that COXIV is significantly reduced by 52% in ρ0 cells compared to 
SY5Y cells (Figure 6), suggesting that ρ0 cells have less mitochondrial mass and that 
cells down regulate mitochondrial proteins when the organelle as a whole is 
dysfunctional. Surprisingly, this reduction in COXIV protein is accompanied by a 68% 
increase in COXIV mRNA. This suggests that at a transcriptional level, ρ0 cells 
upregulate mitochondrial genes, yet at a protein level, reduce the maintenance of proteins 
that are nonfunctional like COXIV. Because the nuclear transcription factors can 
upregulate transcription of COXIV (Scarpulla 1993), we evaluated the key transcription 
factors responsible for regulating mitochondrial proteins. Western blot revealed that 
NRF1 was significantly elevated in ρ0 cells (Figure 7). This protein elevation is 
accompanied by an increase in mRNA transcription. Additionally, transcription of NRF1 
and TFAM was increased in ρ0 cells (Figure 8).  This is consistent with previous reports 
of TFAM and NRF1 gene transcription in HeLa ρ0 cells (Miranda et al., 1999). These 
data suggest that at a transcriptional level, ρ0 cells seem to want to increase mtDNA and 
mitochondrial respiratory proteins, yet are unable to do so; thus we decided to examine 
levels of the master mitochondrial regulator PGC1α. qRT-PCR showed that PGC1α 
mRNA was reduced by 94% in ρ0 compared to SY5Y (Figure 9). Contrary to our TFAM  
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Figure 6. A. The nuclear-encoded cytochrome c oxidase subunit IV protein is reduced in 
ρ0 cells. B. mRNA for this protein is significantly elevated. Error bars represent standard 
deviation, *p<0.001 (student’s two-tailed t-test). 
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Figure 7. A. Nuclear Respiratory Factor 1 protein is significantly elevated by 89% in ρ0 
cells compared to SY5Y. B. NRF1 mRNA expression is significantly increased by 16.5% 
in ρ0 cells compared to SY5Y. Error bars represent standard deviation, **p<0.01, 
*p<0.05 (student’s two-tailed t-test). 
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Figure 8. qRT-PCR revealed that NRF2 and TFAM expression is elevated by 43.7% and 
26%, respectively. Error bars represent standard deviation, **p<0.01, *p<0.05 (student’s 
two-tailed t-test). 
  
59 
 
 
 
 
 
 
 
 
 
 
  
60 
 
 
 
 
 
 
 
 
 
Figure 9. qRT-PCR of SY5Y and ρ0 cells indicates that ρ0 cells express 95% less PGC1α 
mRNA than SY5Y cells. Error bars represent standard deviation, **p<0.001 (student’s 
two-tailed t-test).  
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and NRF findings, this data suggests that ρ0 cells significantly downregulate 
mitochondria as a whole compared to SY5Y by reducing PGC1α mRNA.  
In the absence of PGC1α, we sought to understand the potential regulators 
contributing to the elevated transcription of NRF1, NRF2, and TFAM. Thus, we looked 
at transcription of related proteins PGC1β and PGC1α-related coactivator (PRC). qRT-
PCR revealed that in ρ0cells, PGC1β was elevated by 4.2-fold and PRC elevated 1.9-fold 
compared to SY5Y (Figure 10). Thus, the elevations in TFAM and NRFs may be 
mediated by PGC1β and PRC.  
Regulation of PGC1α transcription 
To better understand the molecular mechanisms governing the reduction in 
PGC1α in ρ0 cells, we looked at two of the established regulators of PGC1α expression: 
CREB and FOXO1. Nuclear expression of FOXO1 was not significantly different 
between SY5Y cells and ρ0 (data not shown). Western blot of phosphorylated CREB 
(pCREB) indicated that pCREB is significantly elevated in ρ0 cells compared to SY5Y 
(Figure 11), suggesting that this signal for PGC1α transcription is increased. 
To understand why pCREB is unable to initiate transcription of PGC1α in ρ0 
cells, we evaluated levels of CREB’s transcriptional coactivator cAMP-regulated 
transcriptional coactivator (CRTC). CRTC can be sequestered in the cytoplasm by 
AMPK phosphorylation of the CRTC/14-3-3 complex CRTC translocation to the 
nucleus, and thus prevent coactivation of CREB transcriptional activation (Altarejos & 
Montminy, 2011). Western blotting revealed that cytoplasmic CRTC is significantly 
elevated in ρ0 cells compared to SY5Y. Importantly, the ratio of nuclear:cytoplasmic 
CRTC was significantly reduced in ρ0 cells (Figure 12). This suggests that activated  
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Figure 10. qRT-PCR revealed that ρ0 cells express 1.9-fold more PRC mRNA (A) and 
4.2-fold higher PGC1β mRNA (B) than SY5Y cells. Error bars represent standard 
deviation, **p<0.001 (student’s two-tailed t-test).  
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Figure 11. Phosphorylation of CREB in ρ0 cells is significantly elevated by 3.4-fold than 
SY5Y cells. Error bars represent standard deviation, **p<0.001 (student’s two-tailed t-
test).  
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Figure 12. Western blot of nuclear and cytoplasmic fractions of SY5Y and ρ0 lysates 
indicate that CRTC protein is greater in the cytoplasm than in the nucleus. The ratio of 
nuclear to cytoplasmic CRTC is significantly lower in ρ0 cells compared to SY5Y. Error 
bars represent standard deviation . *p=0.01, **p<0.01. 
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AMPK prevents CRTC localization to the nucleus, keeping CRTC from coactivating 
CREB transcription of PGC1α.  
PARIS is upregulated in ρ0 cells 
Recent studies have identified a new inhibitor of PGC1α expression, ZNF746 
(PARIS), which binds the insulin response elements in the PGC1α promoter to prevent 
transcription activation (Shin et al., 2011). To better understand the potential role of 
PARIS in regulating transcription of PGC1α, we evaluated levels of PARIS in ρ0 and 
SY5Y cells. Interestingly, we found that PARIS protein levels are significantly elevated 
by four-fold in ρ0 cells compared to SY5Y (Figure 13A).  
Initial characterization of PARIS indicated that PARIS protein levels are 
controlled by ubiquitination by the E3-ubiquitin ligase parkin and subsequent 
proteasomal degradation (Shin et al., 2011). Thus, we looked at protein expression of 
parkin and a known parkin substrate, synaptotagmin XI, to see if ρ0 cells have decreased 
protein levels or activity levels in ρ0 cells. Western blot indicated that ρ0 cells actually 
have increased parkin levels, which correspond to a decrease in parkin’s substrate 
synaptotagmin XI (Figure 14). This data suggests that the elevated PARIS levels we 
observed in ρ0 cells are not due to reduced parkin protein levels or parkin activity. Next, 
we evaluated transcription of PARIS and found that in ρ0 cells, PARIS mRNA levels 
were elevated by 1.8-fold in ρ0 cells (Figure 13B). Thus, we suspect that PARIS levels 
are at least in part regulated by gene transcription; however, because ρ0 cells have four-
fold higher PARIS protein, it is likely that there are some post-translational mechanisms 
protecting PARIS from degradation by parkin. Additionally, it is possible that elevated 
PARIS in ρ0 cells decreases PGC1α mRNA by inhibiting PGC1α transcription. 
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Figure 13. A. PARIS protein is significantly elevated by over 4 fold in ρ0 cells compared 
to SY5Y cells. B. PARIS mRNA is increased by 84% in ρ0 cells. Error bars represent 
standard deviation, **p<0.001 (student’s two-tailed t-test).  
 
 
71 
 
 
  
72 
 
 
 
 
 
 
 
 
 
Figure 14. A. Western blots of parkin and synaptotagmin XI. B. Parkin protein is 
increased by 42% in ρ0 cell compared to SY5Y. C. Synaptotagmin XI protein is reduced 
by 20% in ρ0 cells. Error bars represent standard deviation, **p<0.01, *p<0.05 (student’s 
two-tailed t-test).  
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DISCUSSION 
A number of studies have characterized different aspects of mtDNA-deficient cell 
lines, and ρ0 cells are becoming a popular model for studying oncogenesis and 
neurodegenerative disease (Brar et al., 2012; Ivanov et al., 2011; Magda et al., 2008; 
Masgras et al., 2012; Wojewoda et al., 2012). We believe that ρ0 cells allow us the unique 
opportunity to study the role of mtDNA—and thus mitochondrial function—in a cell’s 
bioenergetic homeostasis.  
We observed that mtDNA-deficient SY5Y cells experience elevated Akt 
signaling. This is likely because without the key respiratory subunits encoded by mtDNA, 
ρ0 cells are functionally unable to generate ATP and NAD+ via mitochondrial MRC and 
must therefore depend on glycolysis, making them bioenergetically stressed. In general, 
Akt signaling is thought to promote non-respiratory energetics (Cheng et al., 2010), and 
many of its known targets may significantly contribute to the downregulation of PGC1α 
we observed (Figure 15) (Cheng et al., 2009; Cheng et al., 2010; Fukuoka et al., 2003; 
Hong et al., 2011; Li et al., 2007; Puigserver et al., 2003). Activated Akt  phosphorylate 
the transcription factor FOXO1, resulting in its transport out of the nucleus and 
subsequent ubiquitination and proteasomal degradation (Daitoku et al., 2003; Matsuzaki 
et al., 2003). This would decrease the nuclear FOXO1 available for PGC1α promoter 
activation, thus decreasing PGC1α transcription. However, we did not find a difference in 
nuclear FOXO1 protein between SY5Y and ρ0 cells, thus the dramatic reduction we 
observed in PGC1α mRNA is probably not a result of a reduction in FOXO1. (Akimoto 
et al., 2005; Barger et al., 2001; Gibala et al., 2009; Hong et al., 2011; Liang et al.; 
Puigserver et al., 2001).  
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Activated Akt can also phosphorylate GSK3β, preventing GSK3β’s inhibition of 
CREB and thus allowing CREB to bind CRE sites on target promoters relatively 
unhindered (Gotschel et al., 2008; Grimes & Jope, 2001). We observed elevated 
phosphorylated GSK3β in ρ0 cells, suggesting that Akt signaling may be at least partially 
responsible for the dramatic increase we observed in activated nuclear CREB in ρ0 cells. 
However, the elevated phosphorylated CREB we observed in ρ0 cells does not appear to 
be associated with an increase in PGC1α expression. Clearly, PGC1α transcription is a 
dynamically regulated process that relies on both metabolic cues and appropriately-
situated signaling molecules.  
Clues into the inability of phosphorylated CREB to result in increased PGC1α 
transcription may come from the elevated AMPK phosphorylation we observed in ρ0 
cells. ρ0 cells operate with a significant reduction in energy status compared to SY5Y 
cells in the form of elevated ADP/ATP ratio, which is consistent with the elevated 
AMPK phosphorylation. Activated AMPK may in turn phosphorylate the CRTC-14-3-3 
complex, preventing CRTC translocation to the nucleus and its subsequent activation of 
CREB transcription of PGC1α (Altarejos & Montminy, 2011; Conkright et al., 2003; 
Iourgenko et al., 2003; Takemori et al., 2007). As we saw a significant increase in ρ0 
cytoplasmic CRTC levels and a significant reduction in ρ0 nuclear:cytoplasmic CRTC 
ratio, this may be why elevated nuclear CREB phosphorylation in ρ0 cells does not result 
in PGC1α transcription, and is another plausible mechanism for PGC1α reduction in ρ0 
cells.  
Phosphorylation of AMPK may also inhibit PGC1α expression via its role in 
mTOR signaling. AMPK may activate the inhibitor of the mTORC1 complex TSC2 to  
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Figure 15. Summary of mechanisms governing PGC1α transcription.  
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prevent mTORC1 from activating PGC1α transcription (Cunningham et al., 2007; Gwinn 
et al., 2008; Hardie, 2008; Inoki et al., 2003a). Additionally, AMPK may directly 
phosphorylate the mTORC1 protein Raptor, further preventing mTORC1 activity (Gwinn 
et al., 2008; Hardie, 2008). As we observed elevated phosphorylation of AMPK and 
decreased activity of mTORC1 in ρ0 cells, this may be a plausible mechanism for the 
inhibition of PGC1α transcription in these cells.  
Recently, a novel inhibitor of PGC1α transcription, termed ZNF746/PARIS, was 
identified (Shin et al., 2011). This protein was found to bind to the PGC1α promoter via 
its insulin response elements to prevent transcription. We found a significant elevation of 
PARIS protein in ρ0 cells compared to SY5Y, which is consistent with its purported role 
as a PGC1α transcription inhibitor. We also examined levels of the E3-ubiquitin ligase 
parkin, which has been shown to target PARIS for proteasomal degradation (Shin et al., 
2011) and found that parkin levels were unexpectedly elevated in ρ0 cells. Additionally, 
parkin’s known target, synaptotagmin XI, was significantly reduced in ρ0 cells compared 
to SY5Y. Together, these data suggest that in ρ0 cells, PARIS levels are not elevated due 
to a reduction in parkin protein or parkin activity. PARIS mRNA, however, was 
significantly elevated in ρ0 cells compared to SY5Y, so it is likely that increased gene 
transcription plays some role in PARIS elevation in ρ0 cells.  
Overall, we have shown that neuroblastoma cell lines devoid of mtDNA operate 
at a significant bioenergetic deficit compared to their wild-type counterparts. These ρ0 
cells display signaling markers suggestive of bioenergetic stress such as activated Akt 
and AMPK. Interestingly, we observed that ρ0 cells dramatically reduce expression of the 
mitochondrial master regulator PGC1α. In understanding the downregulation of PGC1α, 
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we found that the CREB coactivator CRTC was sequestered to the cytoplasm in ρ0 cells, 
possibly due to activated AMPK, and that the PGC1α transcription inhibitor was 
significantly increased in ρ0 cells compared to SY5Y. Despite downregulation of PGC1α, 
we observed increased expression of the nuclear respiratory transcription factors NRF1 
and NRF2. Together, these data suggest that mitochondrial retrograde signaling promotes 
a disconnect between maintaining mitochondrial mass and upregulating respiratory 
subunits, likely due to the fact that dysfunctional mitochondria are a bioenergetic 
liability. Because this study was performed in neuroblastoma cell lines, the information 
produced may be directly relevant to neurological disorders in which mtDNA depletion 
or mutation play a key role.   
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INTRODUCTION 
The ketogenic diet has been used for nearly a century for the treatment of epilepsy 
(A, 1931; Cooder, 1933; Ellis, 1931; Wheless, 2008). Designed to biochemically mimic 
caloric restriction, the ketogenic diet results in the elevated serum ketone bodies 3-β-
hydroxybutyrate (β-OHB), acetoacetate (AcAc), and acetone. While this diet’s popularity 
in clinical medicine has waxed and waned over the years, it continues to pique scientists’ 
interests as to it mechanisms of antiepileptogenesis, and many groups are now working to 
understand the potential role of a ketogenic diet and β-OHB in the treatment of other 
neurological diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis, 
traumatic brain injury, and Parkinson’s disease (Henderson et al., 2009; Imamura et al., 
2006; Masuda et al., 2005; Prins, 2008; Stafstrom & Rho, 2012; Swerdlow et al., 1989; 
Tieu et al., 2003; Van der Auwera et al., 2005; Vanitallie et al., 2005; Yang & Cheng; 
Yao et al., 2011; Zhao et al., 2006).  
Individuals on a ketogenic diet obtain the majority of their daily calories from fat, 
with moderate protein and low carbohydrate contribution. In general, ingested fats are 
delivered to the liver as triacylglycerol and then processed by hepatocytic fatty acid 
oxidation to generate acetyl-CoA (Schugar & Crawford, 2012). During periods of high 
fatty acid load, perivenous hepatocytes convert excess acetyl-CoA to the ketone body 
AcAc via condensation of acetyl-CoA to acetoacetyl-CoA by the enzyme 3-ketothiolase, 
then to acetoacetate by a series of reactions, the first of which is enzyme 3-hydroxy-3-
methylglutaryl (HMG)-CoA synthase (Figure 1) (Garber et al., 1974; Laffel, 1999; 
McGarry & Foster, 1980). AcAc can then be converted to β-OHB by 3-hydroxybutyrate 
dehydrogenase. Under starvation, insulin resistance or insufficiency, or on a ketogenic  
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Figure 1. A. Ketone bodies are generated from excess acetyl-CoA in hepatocytes by 
conversion to acetoacetyl-CoA, then to the intermediate β-hydroxy-β-methylglutaryl-
CoA, and then to acetoacetate. Acetoacetate can then be converted to β-hydroxybutyrate 
via the enzyme D-β-hydroxybutyrate dehydrogenase or spontaneously decarboxylated to 
acetone. B. Acetoacetate and β-hydroxybutyrate can be utilized by tissues and cells such 
as neurons by ketolytic conversion to acetyl-CoA. First β-hydroxybutyrate is converted to 
acetoacetate, then to acetoacetyl-CoA, and then finally to acetyl-CoA where it can serve 
as a carbon to feed the tricarboxylic acid cycle.  
 
  
83 
diet, both AcAc and β-OHB can be transported to tissues from the liver via the blood for 
use as energy to organs unable to utilize fatty acids such as the brain (Laffel, 1999). In 
the blood, acetoacetate can spontaneously decarboxylate to the volatile ketone body 
acetone, which can then be expelled via the lungs, providing an effective measure of 
ketosis and ketoacidosis (Barnett et al., 1969; Musa-Veloso et al., 2002a; Musa-Veloso et 
al., 2002b; Owen et al., 1982; Tassopoulos et al., 1969).  
Once in the circulatory system, AcAc and β-OHB can cross the blood-brain 
barrier via proton-monocarboxylate cotransporters (MCTs)—especially MCT1—
expressed on endothelial cells lining cerebral vessels (Conn et al., 1983; Garcia et al., 
1995; Garcia et al., 1994a; Garcia et al., 1994b; Hawkins & Mans, 1991; Oldendorf, 
1973; Pellerin et al., 1998; Samala et al., 2011). These ketone bodies can then enter 
astrocytes and neurons via MCT1 and MCT2, respectively (Broer et al., 1997; Pellerin et 
al., 2005; Pierre & Pellerin, 2005). Additionally, ketones may be co-transported with 
sodium into neurons via the sodium-coupled monocarboxylate transporter SLC5A8 
(Ganapathy et al., 2008; Martin et al., 2006). After entering cells, β-OHB can be used as 
an energy source by re-conversion to AcAc by 3-hydroxybutyrate dehydrogenase, from 
AcAc to acetoacetyl-CoA by succinyl CoA-oxoacid transferase, and then to acetyl-CoA 
by methylacetoacetyl-CoA thiolase to feed carbon into the TCA cycle (Nelson & Cox, 
2000).  
Because of the ketogenic diet’s long-established efficacy in treating epilepsy, 
scientists have focused on understanding the role of ketone bodies—especially β-OHB—
in the cellular mechanisms of preventing epileptogenesis. In general, studies suggest that 
β-OHB is neuroprotective in vitro and that a ketogenic diet is protective in vivo against 
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excitotoxicity induced by glutamate or kainic acid (Bough et al., 2007; Jeon et al., 2009; 
Lund et al., 2009; Maalouf et al., 2007; Muller-Schwarze et al., 1999; Noh et al., 2006a; 
Noh et al., 2006b; Noh et al., 2003; Xu et al., 2008; Yudkoff et al., 2008).  
It has become widely accepted that β-OHB’s anticonvulsant modalities are due to 
either a change in neuronal metabolic profile or to a change in gene expression, rather 
than due to a change in cerebrospinal fluid electrolyte levels that might render the 
neuronal extracellular milieu less excitatory (Bough et al., 2006; Kennedy et al., 2007). 
Some studies suggest that the ketogenic diet protects neurons against damage caused by 
reactive oxygen species by increasing expression of mitochondrial uncoupling protein or 
glutathione (Davis et al., 2008; Jarrett et al., 2008; Maalouf et al., 2007; Sullivan et al., 
2004). Others postulate that the ketogenic diet alters production/processing of glutamate 
or other excitatory signals (Dahlin et al., 2005; Lund et al., 2009; Xu et al., 2008; 
Yudkoff et al., 2001). Interestingly, many groups are noticing that β-OHB and a 
ketogenic diet alter cell function by affecting mitochondrial metabolism and biogenesis 
(Bough et al., 2006; Milder & Patel, 2011; Srivastava et al., 2012; Sullivan et al., 2004). 
Additionally, β-OHB and a ketogenic diet may alter signaling molecules such as AMPK, 
CREB, and mTOR that are known to have downstream effects on mitochondrial function 
and biogenesis (Jeon et al., 2009; McDaniel et al., 2011; Srivastava et al., 2012; Yamada, 
2008). 
The goal of this study is to better understand the role of a ketogenic diet in 
mitochondrial metabolism and metabolic signaling pathways in mouse brains in hopes of 
using this information for the treatment of neurological disorders that feature bioenergetic 
dysfunction (Swerdlow, 2009).  
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METHODS 
Animal procedures 
All animal protocols and procedures conformed to the NIH guidelines for the care 
and use of laboratory animals, and were approved by the University of Kansas Medical 
Center Animal Care and Use Committee. Five-month old male C57Bl/6J mice (Jackson 
Laboratories, #000664) were randomly assigned to be fed ad libitum one of three diets. 
Caloric content (3.0 kcal/g) for mice on standard rodent chow (n=11) (Teklad Rodent diet 
#8604) was provided by 24.3% protein, 4.7% fat, and 40.2% carbohydrates by weight. 
Caloric content (5.51 kcal/g) for high fat chow (n=15) (BioServ #F1850) consisted of 
20.5% protein, 36% fat, 36% carbohydrates by weight. Caloric content (7.2 kcal/g) for 
ketogenic chow (n=15) (BioServ #F3666) consisted of 8.6% protein, 75.1% fat, and 3.2% 
carbohydrate by weight. After 4 weeks on diet, mice were fasted for 4-6 hours and ~50µL 
of blood was collected via tail snip for blood glucose readings (AccuCheck) and insulin 
assay (ALPCO #80-INSMSU-E01). After 30 days on diet, mice were decapitated and 
tissues rapidly harvested and snap-frozen in liquid nitrogen. Serum was collected and 
analyzed for β-hydroxybutyrate content using a β-hydroxybutyrate assay kit (Pointe 
Scientific #H7587).  
Western Blot 
~50mg of frozen liver and brain tissue was gently homogenized using a Teflon-
glass homogenizer in NE-PER kit cytoplasmic extraction buffer (Pierce #78835) 
containing protease and phosphatase inhibitor cocktail (Pierce #78444) and EDTA, and 
NE-PER kit protocol instructions followed for nuclear and cytoplasmic protein 
extractions. 20µg of total protein was loaded into Criterion TGX SDS-PAGE gels (Bio-
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Rad #567-1085, #567-1084),  subjected to electrophoresis, and transferred to 
nitrocellulose membrane (Whatman Protran #10401196). Blots were blocked in 5% BSA 
(for antibodies to phosphorylated proteins) or 5% milk in PBST for one hour, incubated 
in primary antibody overnight, washed three times with PBST, incubated for one hour in 
secondary antibody (1:2000, Cell Signaling #7074), and then washed three times in 
PBST. Description of antibodies used is located in Table 1. Bands were visualized using 
SuperSignal West Femto Substrate (Thermo Pierce #34096) on a ChemiDoc XRS system 
(Bio-Rad).  
RNA Isolation and Gene Expression/qPCR 
RNA was isolated from ~20µg of liver or brain tissue using TRI reagent (Sigma-
Aldrich #T9424) following standard protocol. Briefly, cells extracts were collected using 
TRI reagent, RNA separated using chloroform, precipitated with isopropanol, and 
washed with 75% ethanol. cDNA was generated using the RT-PCR cDNA kit (Applied 
Biosystems #4368814). qPCR reactions were performed on an ABI Prism 384-well Real 
Time PCR System using Bio-Rad iTaq Master Mix (Bio-Rad #172-5131) and Applied 
Biosystems TaqMan gene expression primers (see Table 2). GAPDH was used as an 
internal reference. 
mtDNA content 
Total tissue DNA was isolated using phenol chloroform isoamyl alcohol as 
previously described (Guo et al., 2009). 2ng of total DNA was loaded into each well of a 
384-well plate with Applied Biosystems TaqMan primers for 18S (genomic) (Applied 
Biosystems #Mm03928990_g1) or 16S (mitochondrial) (Applied Biosystems 
#Mm04260181_s1) DNA. Reactions were performed on an ABI Prism 384-well Real  
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Antibody Name Dilution Source Catalog # 
Cytochrome oxidase subunit IV 
 1:1000 Cell Signaling 4850 
GAPDH 1:2000 Cell Signaling 2118 
HDAC1 1:1000 Thermo Pierce PA1-860 
mTOR 1:1000 Cell Signaling 2983 
Phospho-mTOR (Ser2448) 1:1000 Cell Signaling 5536 
p70 S6 Kinase 1:1000 Cell Signaling 2708 
Phospho-p70 S6 Kinase 
(Thr389) 1:1000 Cell Signaling 9234 
PGC1α 1:1000 Millipore 516557 
TFAM 1:1000 Aviva Biosystems ARP31400_P050 
Tom20 1:500 Santa Cruz Biotechnology sc-136211 
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Table 1: Summary of antibodies used in experiment. 
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Gene name Assay ID 
CREB1 Mm00501607_m1 
GAPDH Mm99999915_g1 
NRF1 Mm01135606_m1 
NRF2 (GABPA) Mm00484598_m1 
TFAM Mm00447485_m1 
COXIV Mm1250094_m1 
TrkB Mm00435422_m1 
TNFα Mm00443260_g1 
PGC1α Mm01208835_m1 
PGC1β Mm00504720_m1 
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Table 2: Summary of ABI Taqman qRT-PCR primers used.  
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Time PCR System. 
Statistics 
When comparing the means of two groups, statistical analyses were performed 
with a student’s two-tailed t-test using Microsoft Excel. One-way ANOVA with Least 
Significant Difference post-hoc analysis was performed to determine significance 
between the means of multiple groups using the software IBM SPSS Statistics. 
 
RESULTS 
Mice on a ketogenic diet have elevated serum ketone bodies 
Serum β-hydroxybutyrate levels are significantly affected by four weeks on diet. 
Compared to mice on standard chow, β-hydroxybutyrate levels were elevated by 
approximately five fold in mice on a ketogenic diet.  The high fat diet did not induce an 
appreciable ketosis (Figure 2).  
Mice on a ketogenic diet have reduced body mass and altered systemic glucose 
and insulin sensitivity 
Prior to initiation of treatment diets, mice weighed on average 31.4g (± 1.9g). 
After four weeks on standard chow, average mass did not significantly change. However, 
after four weeks on a ketogenic diet, mice lost approximately 16.8% of their body 
weight—an average of 5.2g (±1.7g) to weigh a final average mass of 25.6g (± 2.3g). 
Mice on a high fat diet not significantly gain weight, perhaps due to the relatively short 
duration of the protocol and the relative youth of the mice (Figure 3).  
After four weeks on a ketogenic diet, mice displayed reduced fasting blood 
glucose levels compared to mice on standard chow (4.37mmol/L ± 0.99mmol/L versus.   
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Figure 2. Serum β-hydroxybutyrate levels are significantly elevated in mice on a 
ketogenic diet. Error bars represent standard error of the mean. One-way ANOVA 
p<0.001; ***p<0.001 with LSD post-hoc analysis. 
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Figure 3. Mass of each mouse was measured prior to diet initiation and again at the 
study’s conclusion. Mice on standard chow had no net change in mass over the four week 
duration. Mice on a high fat diet had slightly increased mass. Mice on a ketogenic diet 
experienced significant mass loss compared to mice on standard chow. Error bars 
represent standard error of mean. p<0.001, one-way ANOVA; ***p<0.001 with LSD 
post-hoc analysis.  
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Figure 4. A. After four weeks on a ketogenic diet, mice have decreased fasting blood 
glucose levels compared to mice on standard chow. Additionally, mice on a high fat diet 
have elevated fasting blood glucose compared to mice on standard chow. Error bars 
represent standard error of mean. One-way ANOVA between groups p<0.001; 
***p<0.001, *p<0.05 with LSD post-hoc analysis. B. Fasting serum insulin levels are not 
significantly different between groups. Error bars represent standard error of mean. C. 
Peripheral insulin resistance as described as HOMA-IR is significantly reduced in mice 
on a ketogenic diet compared to mice on a high fat diet. Error bars represent standard 
error of mean. One-way ANOVA between groups p<0.05; *p<0.05 with LSD post-hoc 
analysis.  
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7.09mmol/L ± 0.96mmol/L) (Figure 4A). This suggests that mice on a ketogenic diet 
experience an impaired capacity for maintaining constant blood glucose levels, possibly 
due to reduced glycogenic stores in the liver as has been previously described in rats and 
humans (Colle & Ulstrom, 1964; Conlee et al., 1990; Nilsson & Hultman, 1973) 
Additionally, mice on a high fat diet displayed elevated fasting blood glucose 
(8.65mmol/L ± 2.07mmol/L) compared to mice on standard chow. This elevation is 
consistent with previous studies evaluating glucose homeostasis in mice on a high fat diet  
(Guilford et al., 2011; Sandu et al., 2005; Surwit et al., 1988). Combined, these results 
suggest that a ketogenic diet and a high fat diet alter systemic glucose metabolism in 
mice, but not necessarily in equivalent ways.  
While fasting insulin levels were not significantly affected by four weeks on diet 
(Figure 4B), insulin resistance as calculated by Homeostatic Metabolic Assessment 
(HOMA-IR) was significantly affected by diet. Specifically, mice on a ketogenic diet had 
significantly lower insulin resistance than mice on a high fat diet, suggesting that ketotic 
mice may be more sensitive to insulin signaling (Figure 4C).  
Brains from mice on a ketogenic diet have reduced phosphorylation of mTOR 
Previous studies have shown that rats fed a ketogenic diet have reduced brain 
mammalian target of rapamycin (mTOR) signaling (McDaniel et al., 2011). Similarly, we 
observed a significant 11% reduction in phosphorylation of mTOR in mouse brains 
(Figure 5), suggesting that mTOR signaling may be reduced. However, this reduction in 
mTOR phosphorylation was not accompanied by decreased phosphorylation of p70 S6 
kinase (data not shown), suggesting that a ketogenic diet may not act through activation 
of mTORC1-dependent signaling in mouse brains.  
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Brains from mice on a ketogenic diet have elevated CREB expression 
Cyclic AMP response element binding protein (CREB) is a transcription factor known to 
modulate expression of the mitochondrial master regulator peroxisome proliferator-
activated receptor gamma coactivator 1α (PGC1α) and other mitochondrial elements in 
response to metabolic cues (Altarejos & Montminy, 2011; Puigserver et al., 1999). In 
brains from both mice on a ketogenic diet and a high fat diet, we observed a significant 
increase in CREB gene expression (41% and 30% increase, respectively)  
(Figure 6). This suggests that a ketogenic diet upregulates CREB, which may then 
activate transcription of mitochondrial regulatory genes such as PGC1α. 
Mice on a ketogenic diet have altered brain expression of mitochondrial 
regulators 
(PGC1α) is thought to be a master regulator of mitochondrial function and mass 
(Puigserver et al., 1998; Scarpulla, 2011a). Thus, we wanted to evaluate the effect of a 
ketogenic diet on PGC1α in mouse brains. Western blot of mouse brains indicated that 
PGC1α protein was slightly elevated in mice on a ketogenic diet compared to mice on 
standard chow (Figure 7B). Additionally, qRT-PCR showed that PGC1α expression was 
significantly elevated in brains from mice on a ketogenic diet as well as from mice on a 
high fat diet (Figure 7A). Next, we sought to determine if other mitochondrial regulators 
were affected by a ketogenic diet. qRT-PCR revealed that PGC1β—another PGC1 family 
transcriptional coactivator—was elevated by 60% in brains from mice fed a ketogenic 
diet but not from mice on a high fat diet (Figure 8).  
Because PGC1α can affect the levels of other mitochondrial transcription factors, 
we evaluated the levels of the nuclear transcription factors NRF1 and NRF2 and the  
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Figure 5. Phosphorylation of mTOR at Ser2448 is significantly reduced in brains from 
mice on a ketogenic diet. Error bars represent standard error of the mean. **p<0.01; 
student’s two-tailed t-test.  
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Figure 6. Expression of CREB is significantly increased in brains from mice on both a 
high fat diet and a ketogenic diet. Error bars represent standard deviation. One-way 
ANOVA p<0.05; *p<0.05 between Standard Chow and High Fat Diet with LSD post-hoc 
analysis; **p<0.01 between Standard Chow and Ketogenic Diet with LSD post-hoc 
analysis.  
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Figure 7. A. Expression of PGC1α is significantly elevated in brains from mice on a 
ketogenic diet and from mice on a high fat diet. Error bars represent standard error of the 
mean. One-way ANOVA p<0.001; **p<0.001 with LSD post-hoc analysis. B. Protein 
levels of PGC1α are slightly elevated in brains from mice on a ketogenic diet. Error bars 
represent standard error of the mean. 
  
106 
 
 
 
 
 
 
  
107 
 
 
 
 
 
 
 
 
Figure 8. Expression of PGC1β is significantly elevated in brains from mice on a 
ketogenic diet compared to standard chow, but not from a high fat diet. Error bars 
represent standard error of the mean. One-way ANOVA p<0.01; *p<0.01 with LSD post-
hoc analysis.  
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mitochondrial transcription factor TFAM. Interestingly, despite an elevation in PGC1α 
expression, qRT-PCR showed that NRF1 mRNA is significantly reduced in brains from 
mice on both a ketogenic diet (21.8% decrease) and a high fat diet (26.7% decrease) 
(Figure 9A). NRF2 expression, however, was significantly increased in ketotic brains  
(40.5% increase) but not significantly affected in brains from mice on a high fat diet 
(Figure 9B). Additionally, TFAM expression was significantly reduced in brains from  
both mice on a ketogenic diet (24.3% reduction) and a high fat diet (21% reduction) 
(Figure 10).  
Effect of diet on brain mitochondrial mass 
Elevated expression of PGC1α has been associated with an increase in 
mitochondrial biogenesis (Lehman et al., 2000; Wu et al., 1999). Thus, we analyzed 
various markers of mitochondrial mass. First, we isolated DNA from mouse brains, and 
quantified genomic DNA by qPCR of the 18S ribosomal RNA gene and mitochondrial 
DNA by qPCR of the 16S ribosomal RNA gene. Surprisingly, this mtDNA assay showed 
that both a ketogenic diet and a high fat diet significantly reduce mtDNA content in 
mouse brains (Figure 11). This is consistent with our previous finding that TFAM is 
reduced in brains from mice on a ketogenic diet, as TFAM is important in stabilization 
and replication of mtDNA.  
To see if this reduction in mtDNA was a result of reduced total mitochondria, or if 
it is due to a reduction in mitochondrial mass, we examined expression of mitochondrial 
proteins from mouse brains. The constitutively expressed mitochondrial protein 
translocase of outer mitochondrial membrane 20 (TOMM20) can be used as a marker of 
mitochondrial mass (Rehman et al., 2012; Sotgia et al., 2012). Western blot showed that  
109 
 
 
  
110 
 
 
 
 
 
 
 
Figure 9. A. NRF1 expression is significantly reduced in brains from mice on a ketogenic 
diet and from mice on a high fat diet compared to standard chow. Error bars represent 
standard error of the mean. One-way ANOVA p<0.05; *p<0.05 with LSD post-hoc 
analysis. B. NRF2 expression is significantly elevated in mice on a ketogenic diet, but 
relatively unaffected in mice on a high fat diet. Error bars represent standard error of the 
mean. One-way ANOVA p<0.05; **p<0.01 with LSD post-hoc analysis. 
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Figure 10. Expression of TFAM is significantly reduced in brains of mice on a ketogenic 
diet and from mice on a high fat diet compared to standard chow. Error bars represent 
standard error of the mean. One-way ANOVA p<0.01; *p<0.01 with LSD post-hoc 
analysis.  
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Figure 11. Brain mtDNA content is significantly reduced in brains from mice on both a 
high fat and a ketogenic diet. Error bars represent standard error of the mean. One-way 
ANOVA p<0.01; *p<0.05, **p<0.01. 
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TOMM20 is 2.3 times higher in brain lysates from mice on a ketogenic diet compared to 
those from mice on standard chow (Figure 12), suggesting that even though mtDNA 
content is not higher in brains from ketogenic mice, there may still be higher 
mitochondrial mass.  
Next, we examined levels of the respiratory chain protein cytochrome oxidase 
subunit IV (COXIV). qRT-PCR revealed that COXIV expression is unaffected in mice 
on a ketogenic diet, but is significantly decreased by 33% in mice on a high fat diet 
(Figure 13A). This suggests that mice on a high fat diet may downregulate oxidative 
phosphorylation proteins. While COXIV mRNA levels were unaffected by a ketogenic 
diet, Western blot revealed that COXIV protein was significantly elevated by 2.3-fold in  
brains from mice on a ketogenic diet (Figure 13B), suggesting that a ketogenic diet may 
increase mitochondrial respiratory capacity.  
Mice on a ketogenic diet have decreased expression of TNFα  
Inflammation may play an important role in Alzheimer’s disease, epilepsy, and 
other neurodegenerative processes; the pro-inflammatory cytokine tumor necrosis factor 
α (TNFα) specifically has been implicated in Alzheimer’s disease (Baune et al., 2012; 
Hernandez-Romero et al., 2012; McAlpine & Tansey, 2008; Rubio-Perez & Morillas-
Ruiz, 2012). qRT-PCR revealed that mice on a ketogenic diet have significantly reduced 
brain expression of TNFα by 42.6% (Figure 14), suggesting that these mice may have 
reduced inflammation. 
TrkB expression is elevated in brains from mice on a ketogenic diet 
Brain derived neurotrophic factor (BDNF) is a critical neurotrophin in developing 
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Figure 12. Protein levels of TOMM20 are significantly elevated in brains from mice on a 
ketogenic diet. Error bars represent standard error of the mean. *p<0.05, student’s two-
tailed t-test. 
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Figure 13. A. Cytochrome oxidase subunit IV expression is significantly decreased in 
brains from mice on a high fat diet. Error bars represent standard deviation. One-way 
ANOVA p<0.001; **p<0.001 with LSD post-hoc analysis. B. Protein levels of 
cytochrome oxidase subunit IV are significantly elevated in brains from mice on a 
ketogenic diet. Error bars represent standard error of the mean. *p<0.05, student’s two-
tailed t-test.  
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Figure 14. Expression of TNFα is significantly reduced in brains of mice on a ketogenic 
diet. Error bars represent standard error of the mean. One-way ANOVA p<0.05; *p<0.05 
with LSD post-hoc analysis.  
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neurons, and is important in maintaining hippocampal neuron health and long-term 
potentiation (Jia et al., 2010; Kramar et al., 2010; Massa et al., 2010; von Bohlen und 
Halbach). Additionally, BDNF may play a neuroprotective role in epilepsy (Kuramoto et 
al., 2011). BDNF exerts most of its neurotrophic effects in the brain via the receptor 
tropomyosin related kinase B (TrkB). Although BDNF expression in mouse brains was 
not affected by diet (data not shown), qRT-PCR indicated that TrkB expression is 
upregulated by 33.7% in ketogenic diet mouse brains (Figure 15). This suggests that 
brains of mice on a ketogenic diet may be hypersensitized to BDNF, possibly protecting 
them from neurodegeneration.  
 
DISCUSSION 
A ketogenic diet affects markers of metabolic state 
We observed that mice on a ketogenic diet for four weeks had elevated serum β-
hydroxybutyrate levels, decreased body mass, decreased fasting blood glucose, and 
reduced insulin resistance (HOMA-IR). This data is consistent with previous reports of 
ketogenic diet (Schugar & Crawford, 2012). Each of these observations may have an 
impact in the overall neurological health of an individual. Specifically, insulin resistance 
has been associated with cognitive decline, and may be an important risk factor for 
Alzheimer’s disease (Bosco et al., 2011; Burns et al., 2012; van Himbergen et al., 2012). 
Thus, decreased insulin resistance itself may reduce an individual’s risk for developing 
neurological conditions such as Alzheimer’s.  
Brains from mice on a ketogenic diet display metabolic signaling changes that  
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Figure 15. Expression of TrkB is significantly increased in brains of mice on a ketogenic 
diet. Error bars represent standard error of the mean. *p<0.05 student’s two-tailed t-test. 
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may affect mitochondrial function 
mTOR signaling is an important pathway linking metabolic cues such as insulin 
signaling to mitochondrial gene expression (Cheng et al., 2010). Previous studies have 
shown that rats on a ketogenic diet have reduced brain mTOR signaling through the 
mTORC1 complex (McDaniel et al., 2011). Our results indicate that brains from mice on 
a ketogenic diet have reduced phosphorylation of mTOR, yet no difference in 
phosphorylation of the mTORC1 target p70S6 kinase. This may be due to differences in 
administration and duration of diet; the previous study initiated dietary intervention at 
animals’ weaning, yet ours were initiated at 5 months’ of age. Additionally, the duration 
of our dietary intervention was twice as long as in the previous study; thus, it is possible 
that over time, the tissue compensates for prolonged reduction in mTOR signaling, and 
becomes desensitized.  
CREB is an important transcription factor that similarly links metabolic cues to 
mitochondrial gene transcription. Specifically, CREB activation is key to activating 
transcription of PGC1α (Altarejos & Montminy, 2011; Hong et al., 2011). Our results 
showed that transcription of CREB was increased in brains from mice on a ketogenic 
diet, suggesting that CREB is upregulated, and may play a role in increasing transcription 
of mitochondrial regulatory genes such as PGC1α. 
Brains from mice on a ketogenic diet have altered expression of mitochondrial 
transcription factors 
The expression of the major mitochondrial transcriptional coactivator, PGC1α, 
was significantly elevated in brains of mice on a ketogenic diet, and PGC1α protein was 
slightly elevated. PGC1α facilitates the expression of nuclear genes that promote 
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mitochondrial biogenesis and certain mitochondrial activities. Additionally, expression of 
the related transcriptional coactivator PGC1β was significantly elevated. This data 
suggests that brains from mice on a ketogenic diet depend on mitochondria, and try to 
upregulate mitochondrial mass via these PGC1 proteins. Interestingly, of the well-known 
mitochondrial transcription factors that PGC1α controls, both TFAM and NRF1 
expression were significantly reduced, while only NRF2 expression was increased in 
brains from mice on a ketogenic diet.  
Mitochondrial mass and respiratory potential may be affected by diet 
Brain mtDNA content was significantly reduced in mice on a ketogenic diet and 
in mice on a high fat diet, which suggests that mitochondrial mass is may be 
downregulated by these respective diets. TFAM is an important regulator of mtDNA 
(Larsson et al., 1994; Larsson et al., 1998), and its reduction may account for the apparent 
reduction we observed in mtDNA copy number. Although mtDNA content is reduced by 
diet, protein levels of the constitutively expressed mitochondrial protein TOMM20 were 
significantly elevated in brains of mice on a ketogenic diet, suggesting that in spite of the 
reduction in mtDNA, mitochondrial mass may still be elevated.  
Interestingly, while mRNA content of the respiratory chain subunit COXIV was 
unchanged by a ketogenic diet, protein levels of COXIV were significantly elevated. This 
suggests that at a protein level, a ketogenic diet increases respiratory proteins, and may 
improve the brain’s respiratory profile. NRF2 is well-known to upregulate transcription 
of COXIV (Carter & Avadhani, 1994; Carter et al., 1992), and since we observed 
increased NRF2 expression in brains from mice on a ketogenic diet, this may be a 
mechanism for COXIV’s elevation. Additionally, a high fat, high carbohydrate diet 
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decreased mRNA levels of COXIV, further suggesting that mice on this diet reduce their 
ability to rely on mitochondrial oxidative phosphorylation. This data supports the 
findings of a previous study that showed that transcription of mitochondrial DNA is 
significantly elevated in brains from rats fed a ketogenic diet (Bough et al., 2006), and 
suggests that a ketogenic diet may be beneficial in individuals with reduced brain 
mitochondrial function such as Alzheimer’s disease.  
Thus, while brain mtDNA content is reduced in mice on a ketogenic diet, 
mitochondrial proteins are increased. This suggests that mitochondria in brains from mice 
on a ketogenic diet may exist in a highly fused state, such that overall protein mass is 
elevated, but fewer mtDNA chromosomes are needed. Ultrastructural analysis of neurons 
from mice on the different diets would likely provide fascinating insight as to the 
fission/fusion status of mitochondria.  
Ketogenic diet may improve non-mitochondrial cell signaling profiles  
As previously discussed, inflammatory profiles appear to be increased in several 
neurodegenerative disorders. We found that expression of the pro-inflammatory cytokine 
TNFα was significantly reduced in brains of mice on a ketogenic diet. This suggests that 
a ketogenic diet may have anti-inflammatory properties for the brain, and may discourage 
inflammation in neurodegenerative disorders. This is consistent with previous studies 
reporting that a ketogenic diet reduces systemic inflammation in rats (Ruskin et al., 
2009).  
The neurotrophin BDNF is necessary for maintaining hippocampal health, and 
has been a target for the treatment of neurodegenerative disorders, especially Alzheimer’s 
disease. Our results indicate that expression of the canonical BDNF receptor, TrkB, is 
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significantly upregulated in brains of mice on a ketogenic diet. This suggests that a 
ketogenic diet may increase brain sensitivity to BDNF.  
In conclusion, we have demonstrated that a ketogenic diet predisposes mice to a 
number of events that may be beneficial to combating neurodegenerative disorders. First, 
a ketogenic diet reduces peripheral insulin resistance; this in itself may promote overall 
neurological health. Although it did not have an effect on mtDNA content in brains, a 
ketogenic diet seems to increase some aspects of mitochondrial mass and respiratory 
chain proteins. Finally, a ketogenic diet reduced brain expression of the pro-inflammatory 
cytokine TNFα and increased expression of the BDNF receptor TrkB. All of these events 
may prove useful in the treatment of neurological disorders such as epilepsy, Parkinson’s 
disease, and Alzheimer’s disease.  
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Chapter IV: Characterization of cybrids generated from patients with Alzheimer’s 
disease, mild cognitive impairment, amyotrophic lateral sclerosis, older adults, and 
young adults 
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INTRODUCTION 
Cytoplasmic hybrids 
Elucidating the direct contribution of mtDNA to mitochondrial function is 
generally confounded by the bigenomic nature of mitochondrial proteins. This problem 
can be circumvented by the use of cytoplasmic hybrid (cybrid) cells. Cybrid cell lines 
were first generated when investigators transferred chloramphenicol resistance between 
cell lines, thus proving this resistance was conferred by mtDNA (Wallace et al., 1975). 
The technique was later used to transfer mitochondria and mtDNA from platelets (which 
contain mtDNA but no nDNA) to cell lines devoid of mtDNA (ρ0 cells) (Figure 1) (King 
& Attardi, 1988, 1989).  
This technique has given us a tremendous advantage in investigating the role of 
mtDNA in mitochondrial function. Because the background ρ0 cell nDNA is the same for 
a series of cybrid lines, any differences in mitochondrial function comes from differences 
in platelet donor mtDNA, allowing us to explore the role of mtDNA in mitochondrial 
function.  
Mitochondrial dysfunction in cybrids from Alzheimer’s disease and mild 
cognitive impairment 
  As previously discussed, mitochondrial dysfunction lies at the heart of 
Alzheimer’s disease (AD) pathogenesis (Swerdlow et al., 2010; Swerdlow & Khan, 2004, 
2009; Swerdlow et al., 1997b). Cybrid lines containing AD subject mtDNA overproduce 
oxygen radicals, accumulate Aβ, have impairments in mitochondrial transport and have 
decreased ATP levels compared to control cybrid lines containing mtDNA from  
  
131 
 
 
 
 
 
 
 
 
  
132 
 
 
 
 
 
 
 
Figure 1. Generation of cybrid cell lines. Tumor or immortalized cell lines are grown in 
the presence of ethidium bromide, which effectively eliminates functional mtDNA to 
result in a ρ0 cell line. The ρ0 cells express nuclear mitochondrial components, but 
without mtDNA-encoded proteins, the mitochondrial respiratory chain is non-functional. 
ρ0 cells are then fused with a patient’s platelets, which contain mitochondria, but not 
nuclei. This creates cytoplasmic hybrid (cybrid) cells that can be isolated and expanded. 
Differences in function between cell lines most likely arise through differences in their 
mtDNA.  
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unaffected individuals (Cardoso et al., 2004b; Khan et al., 2000; Swerdlow, 2007; 
Trimmer & Borland, 2005). Additionally, cybrids generated from AD patient mtDNA  
exhibit a significant reduction in cytochrome c oxidase (COX) activity, which persists 
over time and passage in culture (Swerdlow, 2007; Swerdlow, 2011c; Swerdlow et al., 
1997b; Trimmer et al., 2004). Since three of the 13 COX subunits are encoded by 
mtDNA, this phenomenon suggests mtDNA differs between AD patients and control 
subjects, and supports the view that mtDNA contributes to the AD-associated COX 
activity reduction.  
Mild cognitive impairment (MCI) is characterized clinically as a subjectively 
experienced and objectively observable cognitive decline syndrome that does not 
irrevocably preclude independent social, occupational, and activity of daily living 
function.  In reality,the MCI syndrome differs from the dementia syndrome mostly in 
terms of depth and degree of dysfunction.. It is thought in the majority of cases to 
constitute a pre-Alzheimer’s state, however little data exist as to the role of mitochondria 
in MCI. One study showed that MCI cybrids have similar mitochondrial dysfunction as 
AD cybrids: MCI and AD cybrids have reduced COX activity, mitochondrial membrane 
potential, and oxidative damage compared to control cybrids (Silva et al., 2012a).  
The goal of this study is to fully characterize the mitochondrial defect conferred 
by mtDNA in AD and MCI.  
Mitochondria and amyotrophic lateral sclerosis 
ALS is associated with mitochondrial defects. Brains and spinal cords from 
individuals with sporadic ALS show elevated signs of oxidative damage, which suggests 
that these tissues experience abnormal mitochondrial function (Bowling et al., 1993; 
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Ferrante et al., 1997). Spinal cords of patients with ALS show significant reductions in 
mitochondrial mass and mitochondrial respiratory complex activity (Borthwick et al., 
1999; Fujita et al., 1996; Wiedemann et al., 2002). These studies indicate that 
mitochondria are significantly impaired in nervous tissue in ALS. Mitochondrial 
dysfunction in ALS may be systemic; liver mitochondria appear dysmorphic (Krasnianski 
et al., 2005; Nakano et al., 1987), skeletal muscle mitochondrial activity is reduced 
(Krasnianski et al., 2005; Vielhaber et al., 2000; Vielhaber et al., 1999; Wiedemann et al., 
1998), and mitochondrial respiratory capacity in lymphocytes is reduced in ALS (Curti et 
al., 1996). Additionally, cybrids generated from platelet mitochondria collected from 
ALS patients have altered calcium homeostasis, increased free radical production, and 
reduced Complex I activity (Swerdlow et al., 2000). These studies provide evidence that 
systemic mitochondrial dysfunction is present in individuals with ALS.  
We plan to more fully evaluate the role of mtDNA and mitochondrial dysfunction 
in ALS by studying the respiratory capacity, mitochondrial respiratory complex activities, 
and retrograde signaling in cybrids generated from ALS patient platelet mtDNA.  
Mitochondria in aging 
The mechanisms of aging and the search for a biological fountain of youth has 
been the source of countless scientific investigations. As the primary machinery for 
setting the cell’s bioenergetic status, the mitochondrion seems well-situated for a 
potential role in aging. Indeed, a plethora of data place mitochondria at the center of cell, 
tissue, and organismal aging. Mitochondrial membrane potential, mass, and respiration 
decrease as a function of age in yeast cultures (Volejnikova et al., 2012). Mitochondrial 
oxidative stress is elevated in brains, liver, and hearts from aged mice and rats (Garcia-
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Fernandez et al., 2011; Srividhya et al., 2009; Tatarkova et al., 2011). Structure and 
function of the mitochondrial respiratory complex is altered in brains, hearts, and kidneys 
from aged rodents (Bagh et al., 2011; Frenzel et al., 2010; Fujioka et al., 2011; Gomez et 
al., 2009; Navarro et al., 2011; O'Toole et al., 2010; Tatarkova et al., 2011). Interestingly, 
mitochondrial function in aged mice of strain known to have extended lifespan is 
significantly higher than in age-matched wild-type mice, suggesting that mitochondrial 
function may contribute to this strain’s extended lifespan (Choksi et al., 2011). Other 
mitochondrial abnormalities are present in various tissues from aged mice and rats such 
as reduced mitochondrial membrane potential (Garcia-Fernandez et al., 2011).  
Mitochondria are not only involved in aging in rodents, but significant evidence 
implicates mitochondrial impairment in aged humans. A recent forensic study showed 
that human tissue samples could be retrospectively “aged” by evaluating cytochrome c 
oxidase activity: COX activity was significantly reduced in tissue samples from older 
individuals (Ishikawa et al., 2011). Muscle biopsies from aging humans show reduced 
mitochondrial mass, mtDNA copy number, mitochondrial respiratory chain function, and 
reduced COX activity compared to muscle biopsies from young controls (Cooper et al., 
1992; Crane et al., 2010; Johannsen et al., 2012; Menshikova et al., 2006; Peterson et al., 
2012; Short et al., 2005; Trounce et al., 1989; Welle et al., 2003), suggesting that age is 
associated with reductions in mitochondria or mitochondrial function in human skeletal 
muscle.  
Clearly, mitochondrial function is impaired in aging. The underlying source of 
this impairment seems to be more difficult to elucidate. Acquired mutations in mtDNA 
may be responsible for mitochondrial decline in aging, as aged individuals have more 
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mtDNA mutations and mtDNA rearrangements than younger individuals (Kovalenko et 
al., 1997; Lin et al., 2002b; Linnane et al., 1989; Melov et al., 1999; Melov et al., 1995; 
Michikawa et al., 1999; Ozawa, 1995; Richter et al., 1988; Swerdlow & Khan, 2004; 
Wallace, 1992; Wang et al., 2001). Additional insight comes from mtDNA mutator mice; 
mice expressing mtDNA polymerase with deficient proofreading develop mutation-heavy 
mtDNA and have significantly reduced lifespan and mitochondrial respiratory chain 
function (Hiona et al., 2010; Trifunovic et al., 2005; Trifunovic et al., 2004; Vermulst et 
al., 2008). Overexpression of PGC1α in hearts and skeletal muscle of these mice results 
in increased mitochondrial biogenesis, attenuation of sarcopenia, and restoration of 
respiratory function to that of wild-type mice (Dillon et al., 2012). Together, these studies 
suggest that mtDNA mutations influence mitochondrial function, and impaired 
mitochondrial function results in aging.  
The goal of our study is to evaluate the effect of donor age on mitochondrial 
function. By generating cybrids, we transfer mtDNA from donors to cells devoid of 
mtDNA; thus, the differences between cell lines generated from older adults and young 
adults should be the result of differences in mtDNA. We expect to see that mtDNA from 
older adults will confer significant impairments in mitochondrial function compared to 
mtDNA from younger adults.  
 
METHODS 
Generation of cybrid lines 
For a visual summary of the generation of cybrids, see Figure 1. Subject blood 
was collected in sterile tubes containing acid citrate dextrose. Inactivated platelets were 
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isolated by centrifuging (1000g x10 minutes) 5mL of whole blood and 3mL Histopaque 
1077 (Sigma-Aldrich #1077) in Leucosep tubes (Greiner #227290) containing a 
polyethylene frit to allow efficient separation of red blood cells from plasma. The plasma 
layer was isolated and further centrifuged for 15min at 1700g to pellet the platelets. The 
platelet pellet was then washed once by resuspending in 5mL SMEM (Gibco #11380), 
and then centrifuged for 15 minutes at 1700g. After the wash step, we aspirated the 
supernatant from the platelet pellet, and carefully added 2 million SH-SY5Y cells 
depleted of mtDNA (ρ0 cells) suspended in 1mL SMEM to the top of the platelet pellet, 
and centrifuged for 3 minutes at 300g. In the meantime, 1mL of sterile polyethylene 
glycol was melted by incubation at 37°C and mixed well with 1mL of SMEM; the pH of 
the resulting solution was adjusted to 7.4. After layering the ρ0 cells with the platelets, we 
removed the supernatant, added 200µL of polyethylene glycol/SMEM, and triturated for 
60sec to fuse platelet and ρ0 cell membranes. These cells were then plated in DMEM with 
high glucose (Gibco #11965) with 10% heat-inactivated FBS, 1% 
penicillin/streptomycin, and 100µg/mL sodium pyruvate and 50µg/mL uridine for one 
week to recover from the stress of fusion. After one week, pyruvate- and uridine-rich 
medium was replaced with medium depleted of pyruvate and uridine (high glucose 
DMEM, 10% dialyzed FBS, 1% penicillin/streptomycin), and cells were grown for 6 
weeks to eliminate cells not fused with platelets (Figure 2), after which time, cells were 
grown in standard growth medium (high glucose DMEM, 10% heat-inactivated FBS, 1% 
penicillin/streptomycin). Lines were passaged approximately 20 times prior to assay. All 
procedures conformed to standards established by the Human Subjects Committee at 
KUMC. For a summary of cell lines generated, see Table 1. 
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Cell line Number of subjects 
Average 
donor age 
Donor age 
range 
Alzheimer’s disease (AD) 10 71.4 58-87 
Mild cognitive impairment 
(MCI) 
7 72 64-83 
Aged control (CON) 8 75.9 65-85 
Young control (Y) 9 29 24-33 
Amyotrophic Lateral Sclerosis 
(ALS) 
13 64.3 36-81 
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Table 1. Summary of cybrids generated.  
140 
 
  
141 
 
 
 
 
 
 
 
 
Figure 2. Selection of cybrids. A. ρ0 cells successfully fused with donor platelets expand 
clonally in medium lacking pyruvate and uridine to yield colonies of cybrids. B. ρ0 cells 
not fused with platelets cannot grow in medium lacking pyruvate and uridine, and thus 
these cells die or become overrun with successful cybrids. 
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Isolation of mitochondria from cybrids 
Approximately 20 million cells per line were trypsinized, pelleted by 
centrifugation at 300g x 3 minutes, washed, and resuspended in ice-cold mitochondrial 
isolation buffer (225mM mannitol, 75mM sucrose, 5mM Hepes, 1mM EGTA, pH 7.4) 
(Kristian et al., 2006). Cells were then subjected to high pressure lysis in nitrogen 
cavitation at 900psi for 15 minutes. The lysate was centrifuged for 5 minutes at 1000g to 
remove cellular debris, then for 10 minutes at 20,000g to pellet the crude mitochondrial 
fraction. The mitochondrial pellet was resuspended in 300µL of mitochondrial isolation 
buffer and frozen at -80°C until use.  
Cytochrome oxidase activity 
Cytochrome c oxidase Vmax was determined spectrophotometrically by 
calculating the pseudo-first order rate constant by measuring the oxidation of cytochrome 
c at 550nm. Briefly, isolated mitochondria or whole cells were incubated in assay buffer 
(20mM potassium phosphate buffer, pH 7.0) and 0.2mg/mL dodecyl maltoside for 2 
minutes at 30°C. 25µM of reduced cytochrome c was added and rapidly mixed. The rate 
of oxidation of cytochrome c was determined by measuring the change in absorbance at 
550nm over 2 minutes, and Vmax determined by calculating the slope of the log of the 
change in absorbance versus time.  
Western blot 
Cell lysates were generated using M-PER mammalian protein extraction reagent 
(Thermo Pierce #78503) per manufacturer’s instructions. After quantification of total 
protein using DC assay (Bio-Rad #500-0112), samples were subjected to SDS-PAGE 
electrophoresis (Bio-Rad #567-1084, #567-1085) and transferred to nitrocellulose 
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membrane (Whatman Protran #10401196). Blots were blocked in 5% BSA in PBST for 
phosphorylated antibodies or in 5% milk in PBST for one hour, then incubated in primary 
antibody overnight, washed three times in PBST, incubated in secondary antibody for one 
hour, and washed three times in PBST. Bands were visualized using SuperSignal West 
Femto Substrate (Thermo Pierce #34096) on a ChemiDoc XRS system (Bio-Rad). 
Antibodies and concentrations used are in Table 2. GAPDH or tubulin was used as an 
internal reference.  
 
RESULTS 
Cytochrome oxidase activity is reduced in AD cybrids 
Previous studies have shown that AD cybrids assayed within several months of 
their production have a significantly reduced COX activity (Onyango et al., 2010a; 
Sheehan et al., 1997a; Swerdlow et al., 1997a; Trimmer et al., 2000), while cell lines 
maintained in continuous culture for more extended periods show a compensatory 
upregulation of mitochondrial synthesis that minimizes this difference (Trimmer et al., 
2004).  Experimental conditions in the current study were consistent with those of the 
Trimmer et al 2004 study, in that lines were maintained in continuous culture for greater 
than 3 months before assayed.  Similar to the results of Trimmer et al 2004, COX activity 
per total cell protein was equivalent between groups (Figure 3).  However, the AD 
cybrids showed a significant increase in COX subunit synthesis, and when COX Vmax 
activities were corrected for COX IV protein,   the AD cybrid COX Vmax activity was 
reduced  relative to that of the control group. (Figure 4). This suggests that AD cybrids  
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Antibody name Concentration Source 
 
Akt 1:1000 Cell Signaling (#4691) 
 
Phospho-Akt (Ser473) 
 
1:1000 Cell Signaling (#4060) 
 
Cytochrome oxidase subunit 
IV 
 
1:1000 Cell Signaling (#4850) 
 
GAPDH 1:2000 Cell Signaling (#2118) 
 
Tubulin 
 
1:1000 Cell Signaling (#2125) 
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Table 2. Summary of antibodies used. 
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Figure 3. Raw cytochrome c oxidase activity is not significantly different in MCI or AD 
cybrids. Error bars represent standard error of the mean. 
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Figure 4. Western blot of cytochrome c oxidase subunit IV is significantly higher in AD 
cybrids and moderately higher in MCI cybrids. *p<0.05, one-way ANOVA with LSD 
post-hoc analysis. Error bars represent standard error of the mean. 
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increase their COX protein levels in order to compensate for a potential COX 
dysfunction. To account for elevated COX protein per cell, we normalized COX activity 
for each cell line to its amount of COXIV protein. We found that COX activity per 
COXIV was significantly reduced in AD cybrids compared to control (Figure 5A). MCI 
cybrids had an intermediate COX activity phenotype compared to AD and control 
cybrids, which suggests that COX activity in MCI is beginning to decline, but has not yet 
reached full dysfunction as in AD.  
Interestingly, when MCI and AD groups were combined in analysis, together they 
had significantly reduced COX activity compared to control cybrids (Figure 5B). This 
further supports the hypothesis that mitochondrial dysfunction is present in MCI at an 
intermediate state to AD and control.  
Data generated by other laboratory members and collaborating investigators 
reveal additional differences between AD and control cybrid cell lines. Using a 
sophisticated system for measuring the rate of oxygen consumption by cells, we found 
that AD cybrids have a significantly impaired maximal respiratory capacity compared to 
controls, and MCI cybrids have a moderately impaired maximal respiratory capacity  
(Silva et al., in preparation). Additionally, AD cybrids have altered mitochondrial 
retrograde signaling and fission/fusion protein levels and post translational modifications. 
MCI cybrids have an intermediate phenotype for every domain investigated. In other 
studies, Dr. Shirley ShiDu Yan’s laboratory has found that AD cybrid cell lines show 
increased processing of the amyloid precursor protein (APP) to beta amyloid. 
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Figure 5. COX activity normalized to COX protein levels. A. COX activity is 
significantly reduced in AD cybrids. The COX activity of MCI cybrids is an intermediate 
state between AD and control. B. When the COX activity of MCI and AD cybrids are 
combined into a single group, the average COX activity is significantly reduced 
compared to control cybrids. **p<0.01, *p<0.05, one-way ANOVA with LSD post-hoc 
analysis. Error bars represent standard error of the mean.  
 
  
153 
Mitochondria from older adults are significantly impaired compared to 
mitochondria from younger adults 
We expected to find that cytochrome oxidase activity would be decreased in 
cybrids generated from aged platelet donors. Indeed, we found that COX activity was 
significantly reduced in whole cells and in isolated mitochondria from cybrids generated 
from older adults compared to cybrids generated from young adults (Figure 6). This 
finding is consistent with the hypothesis that age-associated mtDNA changes have 
functional consequences (Swerdlow & Khan, 2004).  
Next, we analyzed cybrids generated from young versus older adults via western 
blot. Interestingly, we found that phosphorylation of Akt is significantly elevated in 
cybrids from older adults compared to those from younger adults (Figure 7). We are 
currently evaluating the Complex I activities in these cell lines as well as downstream 
effectors of Akt, reactive oxygen species, and mitochondrial retrograde signaling.  
Cytochrome oxidase activity is unaffected in ALS cybrids 
Activity of cytochrome oxidase is not significantly impaired in ALS cybrids 
compared to age-matched controls (Figure 8). This is consistent with previous studies 
that describe a Complex I defect, but normal COX activity (Swerdlow et al., 1998). We 
are currently working to fully characterize the Complex I activities of ALS cell lines as 
well as any differences that may exist in mitochondrial respiratory capacity, 
mitochondrial mass, and retrograde mitochondrial signaling.  
 
DISCUSSION 
By generating these cybrid lines, we have established a sustainable model for 
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Figure 6. COX activity of cybrids generated from young versus older adults. A. COX 
activity in isolated mitochondria is significantly reduced in cybrids generated from older 
adults. B. Raw COX activity in whole cell cybrids generated from older adults is 
significantly reduced. C. COX activity normalized to citrate synthase activity (an 
estimate of mitochondrial mass) in whole cell cybrids generated from older adults is 
significantly reduced. *p<0.05, **p<0.005, ***p<0.001, one-way ANOVA with LSD 
post-hoc analysis. Error bars represent standard deviation.  
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Figure 7. Cybrids generated from older adults have significantly higher phosphorylation 
of Akt. **p<0.01, student’s t-test. Error bars represent standard error of the mean.  
  
158 
 
 
 
 
 
 
 
  
159 
 
 
 
 
 
 
 
 
 
Figure 8. COX activity is unaffected in isolated mitochondria of cybrids generated from 
ALS patients compared to control. 
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studying the role of donor mtDNA on mitochondrial function. We and others will 
continue to use these lines to develop tremendous insight into mitochondrial dynamics. 
Already, we have shown that AD cybrids have significantly impaired COX activity and 
maximal respiratory capacity compared to control cybrids, and that MCI cybrids have a 
phenotype intermediate to that of AD and control cybrids. ALS cybrids have no deficit in 
COX activity compared to control cybrids. And, cybrids generated from aged donors 
have significantly reduced COX activity compared to those generated from young adults, 
accompanied by elevated Akt signaling. We are excited to see the additional insight these 
cell lines will provide. 
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Chapter V: p75NTR is necessary for estradiol-induced remodeling of sympathetic 
nerves in the rodent uterus 
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INTRODUCTION 
Neurodegeneration is the hallmark of a number of clinically and developmentally 
important set of processes. During mammalian development, neural plasticity is arguably 
at its zenith; those neurons making appropriate connections survive, while the significant 
population that do not, undergo degeneration. In many neurodegenerative disorders, the 
major pathologies occur at least in part due to axonal disruption with somal sparing 
(Gould et al., 2006; Mandelkow & Mandelkow, 1998; Sagot et al., 1995). For example, 
studies in mice reveal axonal degenerative changes without effects on neuronal cell 
bodies in the early stages of Alzheimer’s disease (Stokin et al., 2005; Wirths et al., 2006). 
Diabetic peripheral neuropathy is characterized by cycles of axonal degeneration and 
regeneration with relatively little somal involvement (Carson et al., 1980). Despite the 
vast significance of axonopathy in neurodegeneration, relatively little is known regarding 
its mechanisms.  
In recent years, the characterization of sympathetic remodeling in the female 
reproductive tract has emerged as a promising system for studying degenerative 
processes. In the human and rodent uterus, high estrogen levels—such as occur during 
pregnancy and the menstrual/estrous cycle—induce sympathetic denervation of the 
myometrium (Brauer et al., 1995; Haase et al., 1997; Morizaki et al., 1989; Zoubina et 
al., 1998). This denervation is characterized by axolemmal disruption, organelle 
disintegration, and other degenerative events within those axons directly innervating 
myometrium as evidenced by electron microscopy (Zoubina & Smith, 2000). Normal 
remodeling has been thought to positively affect fertility by enabling normal uterine 
contractility and motility during gamete transport (Quinn, 2004b), preventing fetal-
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maternal ischemic episodes, and by decreasing the tendency for spontaneous contractions 
during pregnancy (Brauer, 2008; Klukovits et al., 2002). Pathological sympathetic 
remodeling may contribute to spontaneous abortion, pre-eclampsia, and endometriosis 
(Dong et al., 2007; Quinn, 2004a, 2005). Thus, in itself, sympathetic remodeling of the 
uterus is an important phenomenon that deserves a thorough mechanistic examination. 
The goal of this study is to elucidate the mechanisms governing sympathetic myometrial 
remodeling, and provide the ground work for future parallels to be made with other forms 
of axonal degeneration. 
Estrogen acts directly on myometrial smooth muscle cells to make them 
“repulsive” to sympathetic fibers (Krizsan-Agbas & Smith, 2002). One of these repulsive 
events is the increased expression of brain-derived neurotrophic factor BDNF. Elevated 
BDNF expression and release by myometrium after estrogen treatment is associated with 
the decrease in sympathetic innervation. Elimination of BDNF—either in BDNF-
knockout mice or via neutralizing antibodies—attenuates the response of sympathetic 
nerves to estradiol’s effects (Krizsan-Agbas et al., 2003). Thus, BDNF is an important 
mediator of sympathetic remodeling of the uterus.  
Sympathetic fibers express very little if any of the canonical BDNF receptor TrkB 
(Garcia-Suarez et al., 1996). Because of this apparent sympathetic absence of TrkB, the 
key initiator of denervation BDNF must act through an entirely TrkB-independent 
mechanism. The low-affinity neurotrophin receptor p75NTR is highly expressed in 
sympathetic neurons (Garcia-Suarez et al., 1996; Richeri et al., 2005). p75NTR has a 
varied role in different cell types and environments, with the overall effects ranging from 
apoptosis to cell survival and growth, depending on the ligand and the subcellular milieu. 
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In developmental experiments, BDNF activates p75NTR to result in degenerative events 
such as axon blebbing, and ultimately leads to developmental sympathetic axon pruning 
(Singh et al., 2008).  
We propose that p75NTR is necessary for estradiol-induced denervation of 
myometrial sympathetic nerves, likely by activation by BDNF from uterine smooth 
muscle (Figure 1). 
METHODS 
Mice 
To investigate the role of p75NTR in sympathetic remodeling of the uterus, we 
used mice with a null mutation for p75NTR (Lee et al., 1992) on a C57Bl/6J background. 
p75NTR-/- mice (generous gift from Dr. Beth A. Habecker) and wild-type C57Bl/6J mice 
(Jackson Laboratories, Bar Harbor, Maine, USA) were ovariectomized at 9 weeks of age 
to eliminate circulating levels of reproductive hormones. Seven days after ovariectomy, 
mice were injected with either 10µg/kg 17β-estradiol or sesame oil vehicle. Mice were 
euthanized 24 hours after injection. 
Cryosectioning and immunohistochemistry 
Just after euthanasia, uterine horns were harvested and fixed for three hours in 
Zamboni’s fixative. After sufficient washing in PBS, uteri were cryopreserved in 
mounting medium and cryosectioned at 10µm thickness. To assess overall innervation of 
the myometrium, we immunostained for the pan-neuronal marker protein gene product 
(PGP) 9.5 (1:1000, AbD Serotec, Oxford, UK). To assess sympathetic innervation, we 
immunostained for tyrosine hydroxylase (1:200, Abcam, Cambridge, UK).  
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Figure 1: Schematic of study hypothesis. Sympathetic nerves richly innervate myometrial 
smooth muscle. In high estrogen conditions, 17β-estradiol upregulates expression of 
BDNF to cause degeneration of sympathetic nerves. We hypothesize that elevated BDNF 
caused by 17β-estradiol activates p75NTR to denervate of sympathetic nerves. 
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Image acquisition and analysis 
After immunostaining, slides were coded and evaluated blindly. Images were 
obtained every 150µm from the ovarian end. Three images were obtained per section one 
image at the antimesometrial pole, and one at each perimesometrial junction. Apparent 
nerve density was assessed by counting nerve intersections on a randomly placed 10µm2 
stereological grid (AnalySIS software) divided by the uterine smooth muscle area per 
image. Vascular sympathetic innervation was excluded from nerve counts, because it has 
previously been shown to be unaffected by estrogen treatment (Zoubina et al., 1998). All 
procedures with mice conformed to NIH guidelines and were approved by the University 
of Kansas Medical Center Animal Care and Use Committee. 
RESULTS 
Staining with the pan-neuronal marker PGP9.5-ir revealed that ovariectomized 
mice have high levels of myometrial innervation, and that wild-type mice experience 
significant reductions in overall myometrial innervation with estradiol treatment (Figures 
2 and 3). These results are consistent with previous studies indicating that wild-type mice 
experience dynamic uterine smooth muscle nerve remodeling in response to changes in 
estrogen levels (Zoubina et al., 1998; Zoubina et al., 2001). To examine the role of 
p75NTR in estradiol-induced myometrial nerve remodeling, we quantified PGP9.5-ir 
fibers in uteri from p75NTR-/- mice. We found that innervation was not significantly 
affected by estradiol treatment in uteri from p75NTR-/- mice. Interestingly, PGP9.5-ir 
staining revealed that myometrial tissue from vehicle-treated p75NTR-/- mice is 
hyperinnervated by approximately 2-fold compared to vehicle-treated WT.  
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Figure 2: PGP9.5 fibers in uterine sections. A. Uteri from ovariectomized wild-type mice 
show innervation of myometrial smooth muscle. B Innervation of myometria is 
significantly reduced in wild-type mice when treated with 17β-estradiol. C. Uterine 
smooth muscle from ovariectomized p75NTR-/- mice are richly innervated. D. 
Innervation of p75NTR-/- mice is not significantly reduced with estradiol treatment. 
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Figure 3: 17β-estradiol treatment significantly reduces density of PGP9.5-ir nerves in the 
WT myometrium, but not in p75NTR-/-. Uteri from p75NTR-/- mice have 2-fold higher 
PGP9.5-ir innervation than from WT mice. Error bars represent standard deviation, 
*p<0.05, student’s two-tailed t-test. 
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To establish that the differences observed with PGP9.5 staining were indicative of 
changes in sympathetic innervation as previously reported (Zoubina et al., 2001), we 
stained uterine sections for the sympathetic marker tyrosine hydroxylase (TH). TH-ir 
staining revealed similar results as with PGP9.5 staining: WT mice experience significant 
reductions in sympathetic innervation of uterine smooth muscle in response to estrogen 
(Figures 4 and 5). Sympathetic innervation of myometria in p75NTR-/- mice, however, is 
unaffected by estradiol. As seen with PGP9.5-ir staining, p75NTR-/- uteri had higher 
sympathetic innervation compared to WT mice.  
 
DISCUSSION 
We discovered in this study that p75NTR is necessary for the physiological 
phenomenon of estradiol-induced sympathetic nerve remodeling in uterine myometrial. 
As previously described, estradiol treatment of ovariectomized mice causes significant 
denervation of sympathetic nerves in the uterus (Zoubina et al., 2001; Zoubina & Smith, 
2000). We found here that the absence of functional p75NTR attenuates this denervation, 
suggesting that p75NTR is a key mediator of sympathetic remodeling in the uterus.  
The sympathetic hyperinnervation of p75NTR-/- myometria observed in this study is an 
especially interesting phenomenon. Initial characterization of p75NTR-/- mice indicated 
nerve disruptions in various targets (Lee et al., 1994a; Lee et al., 1994b), many of which 
were likely due to differences in development and differentiation of nerves. Similarly in 
the uterus, the sympathetic hyperinnervation observed in p75NTR-/- mice may indicate a 
developmental disruption of normal prepubertal innervation levels of the myometrium.  
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Figure 4: TH-ir staining in uterine horns. A. Uterine horns from wild-type ovariectomized 
mice have rich innervation of TH-ir positive fibers. B. TH-ir positive nerves are 
significantly reduced in uteri from wild-type mice treated with 17β-estradiol. C. 
Ovariectomized p75NTR-/- mice have very dense TH-ir positive innervation of 
myometrial tissue. D. Uteri from p75NTR-/- mice treated with estradiol have no 
significant reductions in TH-ir fibers.  
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Figure 5. Uterine smooth muscle from wild-type mice experiences significant reductions 
in TH-ir nerves after 17β-estradiol treatment. However, myometrial TH-ir innervation in 
p75NTR-/- mice is unaffected by estradiol. Error bars represent standard deviation, 
*p<0.05, student’s two-tailed t-test.  
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Studies indicate that uteri from pre-pubertal rats are significantly hyperinnervated 
compared to post-pubertal, and that a female rat’s initial dose of estrogen induces 
significant pruning of sympathetic nerves to the myometrium. These pre-pubertal levels 
of high innervation do not seem to be reacquired at any point in the animal’s life, even in 
low estrogen periods such as estrus (Brauer et al., 2002; Brauer et al., 1995). 
Additionally, activation of p75NTR by BDNF can induce degenerative changes in 
sympathetic neurites (Singh et al., 2008). Thus, the hyperinnervation observed in 
p75NTR-/- mice in the present study may simply reflect an inability of sympathetic fibers 
to respond to the degenerative signals (i.e. BDNF) produced by the myometrium in 
response to estrogen—either at the time of puberty or throughout the estrous cycle. 
Alternatively, because BDNF-p75NTR may be antagonistic toward NGF-TrkA growth 
signals (Kohn et al., 1999; Singh et al., 2008), the absence of p75NTR in the present 
study may allow relative unrestricted growth by sympathetics in response to NGF-TrkA.  
Many studies suggest that p75NTR is necessary for high-affinity NGF-TrkA 
activation, especially in low NGF environments (Esposito et al., 2001; Hempstead et al., 
1991; Hempstead et al., 1990; Lee et al., 1994b; Ryden et al., 1997). However, when 
NGF is not limiting, p75NTR may actually inhibit the actions of NGF on TrkA. For 
example, sympathetic nerves aberrantly invade the optic tract in mice overexpressing 
NGF; however, when p75NTR is missing in mice that overexpress NGF, this aberrant 
sympathetic innervation is dramatically enhanced (Hannila & Kawaja, 1999). Similarly, 
in NGF transgenic mice, deep white matter of the cerebellum and trigeminal ganglionic 
neuropil are hyperinnervated by sympathetic nerves; in NGF transgenic mice lacking 
functional p75NTR, this sympathetic hyperinnervation is dramatically enhanced (Dhanoa 
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et al., 2006). These studies suggest that when NGF levels are high, p75NTR may actually 
inhibit sympathetic outgrowth. Some have suggested that p75NTR may act in this 
manner by sequestering excess NGF (Dhanoa et al., 2006; Miller et al., 1994). 
Alternatively, p75NTR may alter the structure, binding, and kinetics of NGF-TrkA 
complexes (He & Garcia, 2004; Singh et al., 2008; Zaccaro et al., 2001). Thus, the 
hyperinnervation we observed in uteri from p75NTR-/- mice may be due to the absence 
of inhibitory regulation of NGF-TrkA signaling from p75NTR.  
This study provides strong evidence for the necessity of p75NTR in estrogen-
induced sympathetic remodeling of the uterus. We show that in the absence of p75NTR, 
sympathetic fibers are unable to respond to signals produced by myometrial smooth 
muscle in response to estradiol. Previous studies show that estradiol increases BDNF 
upregulation in rodent myometrium, which corresponds to reductions in sympathetic 
outgrowth (Krizsan-Agbas et al., 2003). Before now, the mechanisms governing this 
phenomenon have been unexplained due to the absence of TrkB on sympathetic nerves. 
In this study, we present strong evidence that p75NTR is necessary for pruning of 
sympathetic nerves in mouse myometrium, most likely by activation of BDNF released 
by uterine smooth muscle in response to estradiol. 
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Intricacies of mitochondrial signaling pathways in cells lacking mtDNA 
Anterograde and retrograde mitochondrial signaling pathways are incredibly 
intricate and can respond to minute changes in metabolic status of the cell. We showed 
that cells lacking mtDNA (ρ0 cells) have dramatically altered mitochondrial signaling as 
compared to their wild-type parent cells. Specifically, we found that expression of the 
master mitochondrial regulator PGC1α was significantly downregulated in ρ0 cells 
despite elevation of a number of signaling events that would otherwise promote 
expression of PGC1α such as CREB phosphorylation. This inhibition of PGC1α 
expression was associated with reduced expression of nuclear-encoded electron transport 
chain subunits such as COXIV.  To better understand the mechanisms of PGC1α 
downregulation in ρ0 cells, we examined protein levels of PARIS, which has recently 
been shown to prevent PGC1α transcription by blocking activation of the three insulin 
response elements on the PGC1α promoter. We found an elevation in PARIS protein; this 
elevation did not appear to be due to a reduction in parkin levels or activity, which has 
been shown to target PARIS via ubiquitination.  
Interestingly, we found that despite a significant reduction in PGC1α, 
transcription of the genes TFAM and NRF1 were significantly increased in ρ0 cells. This 
suggests that at a molecular level, cells without mtDNA try to increase mtDNA copy 
number and some respiratory genes, while trying to minimize the metabolic strain of 
producing mitochondrial elements that as a whole are non-functional. Because we found 
an increase in the PGC1α-family of transcriptional coactivators PGC1β and PRC, these 
transcription factors may be responsible for the elevated TFAM and NRF1 expression we 
observed.  
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Overall, this study provides data regarding the signaling mechanisms governing 
the interplay between metabolic cues and mitochondrial function, and can provide insight 
into disorders in which mitochondrial dysregulation and dysfunction may play a central 
role, such as Alzheimer’s disease and other neurodegenerative disorders. 
Effect of a ketogenic diet on mitochondrial signaling 
Because mitochondrial dysfunction has functional metabolic consequences, we 
evaluated how diet could affect brain bioenergetic infrastructures in mice. We found that 
mice on a ketogenic diet for four weeks experienced a number of phenomena that may 
improve mitochondrial and neurological health, and may promote an anti-
neurodegenerative state. Metabolically, we found that both fasting glucose and insulin 
resistance were significantly reduced in mice on a ketogenic diet, which may reduce the 
risk of developing a neurodegenerative disorder. We also found that expression of the 
master regulators of mitochondrial function PGC1α and PGC1β were significantly 
upregulated in a ketogenic diet, suggesting that mitochondrial mass and function may be 
enhanced. Although we did not observe differences in mtDNA content in brains from 
mice on a ketogenic diet, we did find that mice on a ketogenic diet have elevated brain 
TOMM20 protein, suggesting that mitochondrial mass may be elevated. We also 
observed an increase in the electron transport chain protein COXIV, which implies that 
brains of mice on a ketogenic diet may have enhanced mitochondrial function compared 
to control.  
Interestingly, we found that in mice on a ketogenic diet, expression of the 
inflammatory cytokine TNFα was significantly reduced, which may further promote an 
anti-degenerative state, and expression of the BDNF receptor TrkB was significantly 
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upregulated, which may enhance the effects of this neuroprotective neurotrophic factor. 
Altogether, this study provides strong evidence for the use of a ketogenic diet in the 
treatment or prevention of neurological disorders.  
Role of mtDNA in neurodegenerative diseases and aging 
To investigate the role of mtDNA in AD, MCI, ALS, and aging, we generated a 
number of cybrid cell lines. We found that cytochrome oxidase activity is significantly 
impaired in cybrids generated from AD patient mtDNA, and is intermediately impaired in 
MCI. We found that cytochrome oxidase activity is unaffected in ALS. Interestingly, we 
discovered that cytochrome oxidase activity is significantly impaired in cybrids generated 
from older adults compared to those generated from young adults. Additionally, cybrids 
from older adults have elevated Akt signaling, suggesting that these lines rely more 
heavily on anaerobic metabolism than do cybrids generated from young adults. 
Altogether, these cell lines will provide incredibly useful data and insight into the role of 
mtDNA in neurodegenerative diseases and aging. 
Role of p75NTR in physiological sympathetic nerve remodeling 
The cyclical phenomenon of sympathetic nerve remodeling of the uterus provides 
a unique process for studying degenerative and regenerative nerve processes in an in vivo 
system. Here, we showed that the degenerative remodeling process of sympathetic nerves 
to the rodent myometrium is dependent upon expression of the pan-neurotrophin receptor 
p75NTR. This data provides further insight into how this phenomenon occurs as well as 
into the function of the multi-faceted p75NTR. Further investigation may result in 
fascinating data that could translate into potential therapies for individuals with 
neurodegenerative disorders.  
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Summary 
Neurodegenerative diseases are incredibly debilitating, and few disease-
modifying treatments exist for those suffering. Extensive research continues to reveal that 
metabolic dysregulation and mitochondrial dysfunction lie at the core of 
neurodegeneration. In Alzheimer’s disease, by far the most prevalent neurodegenerative 
disease in the United States, numerous mitochondrial abnormalities exist—many prior to 
clinical signs or functional loss (Swerdlow, 2011b). These present in the form of 
reductions electron transport chain activity both in AD brains and systemically (Parker et 
al., 1990; Parker et al., 1994b; Trimmer et al., 2004), increased brain and systemic 
oxidative stress (Castegna et al., 2002b; Mecocci et al., 1994; Mecocci et al., 2002; 
Mecocci et al., 1998; Migliore et al., 2005; Pratico et al., 1998), abnormal mitochondrial 
morphology (Saraiva et al., 1985), transport (Trimmer & Borland, 2005), apoptosis (Broe 
et al., 2001; Troncoso et al., 1996), autophagy (Cataldo et al., 1995; Nixon et al., 2005; 
Nixon & Yang, 2011), and fission/fusion (Manczak et al., 2011; Wang et al., 2008a; 
Wang et al., 2009). While neurodegenerative mitochondrial abnormalities are perhaps the 
best documented in AD, they are also present and play a crucial role in the development 
of other neurodegenerative disorders such as Parkinson’s disease, amyotrophic lateral 
sclerosis, and Huntington’s disease (Arduino et al., 2012; Baloyannis et al., 2006; Beal, 
1998; Browne & Beal, 1994; De Vos et al., 2007; Lezi & Swerdlow; Reddy & Shirendeb, 
2011; Sterky et al., 2011; Swerdlow et al., 1998; Swerdlow et al., 2000). Given the 
critical role mitochondria play in normal brain function, and the dramatic degenerative 
events that occur when this goes awry, a thorough understanding of the intricacies of 
mitochondrial metabolism will certainly be key to the development of disease-modifying 
184 
treatments or prevention of neurological disorders. We hope that the work presented in 
this dissertation will inspire and advance the field to eventually relieve the suffering so 
many individuals experience with neurodegenerative diseases.  
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